INHIBITOR OF p38 MAP KINASE

ABSTRACT

A compound has the following formula: 
     
       
         
         
             
             
         
       
     
     The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

Any and all applications for which a foreign or domestic priority claimis identified in the Application Data Sheet as filed with the presentapplication are hereby incorporated by reference under 37 CFR 1.57.

FIELD OF THE INVENTION

The invention relates to a compound which is an inhibitor of the familyof p38 mitogen-activated protein kinase enzymes (referred to herein asp38 MAP kinase inhibitors), for example the alpha and gamma kinasesub-types thereof, and the Src family of tyrosine kinases, and to itsuse in therapy, including in pharmaceutical combinations, especially inthe treatment of inflammatory diseases, in particular inflammatorydiseases of the lung, such as asthma and COPD, as well as those of thegastrointestinal tract, such as ulcerative colitis, Irritable BowelDisease (IBD) and Crohn's disease and of the eye, such as uveitis.

BACKGROUND OF THE INVENTION

Four p38 MAPK isoforms (alpha, beta, gamma and delta respectively), havebeen identified each displaying different patterns of tissue expressionin man. The p38 MAPK alpha and beta isoforms are found ubiquitously inthe body, being present in many different cell types. The alpha isoformis well characterized in terms of its role in inflammation. Althoughstudies using a chemical genetic approach in mice indicate that the p38MAPK beta isoform does not play a role in inflammation (O'Keefe, S. J.et al., J. Biol. Chem., 2007, 282(48), 34663-71), it may be involved inpain mechanisms through the regulation of COX2 expression (Fitzsimmons,B. L. et al., Neuroreport, 2010, 21(4), 313-7). These isoforms areinhibited by a number of previously described small molecular weightcompounds. Early classes of inhibitors were highly toxic due to thebroad tissue distribution of these isoforms which resulted in multipleoff-target effects of the compounds. Furthermore, development of asubstantial number of inhibitors has been discontinued due tounacceptable safety profiles in clinical studies (Pettus, L. H. andWurz, R. P., Curr. Top. Med. Chem., 2008, 8(16), 1452-67). As theseadverse effects vary with chemotype, and the compounds have distinctkinase selectivity patterns, the observed toxicities may bestructure-related rather than p38 mechanism-based. More recently,compounds with greater potency and specificity for p38α/β MAPK have beendeveloped; however, levels of efficacy achieved in the treatment ofchronic inflammatory diseases, including rheumatoid arthritis (SC10-469,Genovese et al., J. Rheumatol., 2011, 38, 846-54; Pamapimod, Cohen etal., Arthritis Rheum., 2009, 60, 335-344; BMS-582949, Schieven et al.,Arthritis Rheum., 2010, 62, Suppl. 10:1513) and COPD (Losmapimod, Watzet al., Lancet Resp. Med., 2014, 2, 63-72) have been disappointing.Furthermore, it is noteworthy that a p38 MAPK inhibitor was found todeliver benefit for patients with IBD after one week's treatment whichwas not sustained over a four week course of treatment (BIRB-796,Schreiber, S. et al., Clin. Gastro. Hepatology, 2006, 4, 325-334).

An important conclusion drawn from these studies is that use of a targetspecific kinase inhibitor may not be sufficient to achieve and sustaintherapeutic benefit in complex inflammatory diseases, wheredysregulation of multiple immuno-inflammatory pathways and biologicaladaption can by-pass blockade of a single target mechanism, resulting inthe loss of response. It can be argued that for complex inflammatorydisease such as COPD, rheumatoid arthritis and IBD, inhibitors thattarget a set of kinases that are critical for regulation of thedifferent immuno-inflammatory mechanisms linked to pathology will havegreater potential to achieve efficacy and a sustained therapeuticresponse.

The role of p38 MAPK-alpha in the regulation of inflammatory pathwayshas been investigated extensively and is well established. Less is knownabout the p38 MAPK gamma and delta isoforms, which, unlike the alpha andbeta isozymes are expressed in specific tissues and cells. The p38MAPK-delta isoform is expressed more highly in the pancreas, testes,lung, small intestine and the kidney. It is also abundant in macrophagesand detectable in neutrophils, CD4+ T cells and in endothelial cells(Shmueli, O. et al., Comptes Rendus Biologies, 2003, 326(10-11),1067-1072; Smith, S. J. Br. J. Pharmacol., 2006, 149, 393-404; Hale, K.K., J. Immunol., 1999, 162(7), 4246-52; Wang, X. S. et al., J. Biol.Chem., 1997, 272(38), 23668-23674). Very little is known about thedistribution of p38 MAPK gamma although it is expressed more highly inbrain, skeletal muscle and heart, as well as in lymphocytes andmacrophages (Shmueli, O. et al., Comptes Rendus Biologies, 2003,326(10-11), 1067-1072; Hale, K. K., J. Immunol., 1999, 162(7), 4246-52;Court, N. W. et al., J. Mol. Cell. Cardiol., 2002, 34(4), 413-26;Mertens, S. et al., FEBS Lett., 1996, 383(3), 273-6). Evidence that thep38 MAPK-gamma and p38 MAPK-delta kinases are expressed inimmunologically important and pro-inflammatory cell types has raisedinterest in their functions relative to p38 MAPK-alpha. Selective smallmolecule inhibitors of p38 MAPK gamma and p38 MAPK delta are notcurrently available to assess the roles of these kinasespharmacologically, although one previously disclosed compound, BIRB 796,is known to possess pan-isoform inhibitory activity. The inhibition ofp38 MAPK gamma and delta isoforms is observed at higher concentrationsof the compound than those required to inhibit p38 MAPK alpha and p38beta (Kuma, Y., J. Biol. Chem., 2005, 280, 19472-19479). In additionBIRB 796 also impaired the phosphorylation of p38 MAPKs or JNKs by theupstream kinase MKK6 or MKK4. Kuma discussed the possibility that theconformational change caused by the binding of the inhibitor to the MAPKprotein may affect the structure of both its phosphorylation site andthe docking site for the upstream activator, thereby impairing thephosphorylation of p38 MAPKs or JNKs.

p38 MAP kinase is believed to play a pivotal role in many of thesignalling pathways that are involved in initiating and maintainingchronic, persistent inflammation in human disease, for example, insevere asthma and in COPD (Chung, F., Chest, 2011, 139(6), 1470-1479).There is now an abundant literature which demonstrates that p38 MAPkinase is activated by a range of pro-inflammatory cytokines and thatits activation results in the recruitment and release of additionalpro-inflammatory cytokines. For instance Smith describes the inhibitoryeffect of p38 MAP kinase inhibitors on TNFα release from human PBMCs.However, the production of some cytokines (IL-8 and GM-CSF) by lungtissue macrophages isolated from smokers and ex-smokers was relativelyinsensitive to p38α/β MAPK inhibitors and Smith suggests that theabundance of p38 MAPK-delta expressed in these cells might account forthe diminished effects of the compounds (Smith et al., Br. J.Pharmacol., 2006, 149, 393-404). Risco et al., (Proc. Natl. Acad. Sci.U.S.A., 2012, 109, 11200-11205) have used p38 MAPK-gamma and p38MAPK-delta gene knockout mice to investigate the roles of these p38isoforms in pathways regulating cytokine production by macrophages.These studies established that in mice both kinases are essential forinnate immune inflammatory responses including proinflammatory cytokineproduction. More recently, Criado, G. et al., (Arthritis Rheum., 2014,66(5), 1208-17) have demonstrated that in a mouse model of inflammatoryarthritis reduced disease severity in p38γ/δ−/− mice was associated withlower cytokine production and immunological activation than in normalcontrol mice, indicating that p38 MAPK gamma and p38 MAPK delta arecrucial regulators of inflammatory joint pathology. These findingssuggest that in addition to p38 MAPK alpha, p38 MAPK gamma and p38 MAPKdelta are potential therapeutic targets in complex diseases that involveinnate and adaptive immune responses such as COPD.

The use of inhibitors of p38 MAP kinase in the treatment of chronicobstructive pulmonary disease (COPD) has also been investigated. Smallmolecule inhibitors targeted to p38 MAPK a/8 have proved to be effectivein reducing various parameters of inflammation in cells and in tissuesobtained from patients with COPD, who are generally corticosteroidinsensitive, (Smith, S. J., Br. J. Pharmacol., 2006, 149, 393-404) aswell as in various in vivo animal models (Underwood, D. C. et al., Am.J. Physiol., 2000, 279, L895-902; Nath, P. et al., Eur. J. Pharmacol.,2006, 544, 160-167). Irusen and colleagues have also suggested thepossible involvement of p38 MAPK α/β with corticosteroid insensitivityvia the reduction of binding affinity of the glucocorticoid receptor(GR) in nuclei (Irusen, E. et al., J. Allergy Clin. Immunol., 2002, 109,649-657). Clinical experience with a range of p38 MAP kinase inhibitors,including AMG548, BIRB 796, VX702, SCIO469 and SCIO323 has beendescribed (Lee, M. R. and Dominguez, C., Current Med. Chem., 2005, 12,2979-2994).

COPD is a condition in which the underlying inflammation is reported tobe substantially resistant to the anti-inflammatory effects of inhaledcorticosteroids. Consequently, a superior strategy for treating COPDwould be to develop an intervention which has both inherentanti-inflammatory effects and the ability to increase the sensitivity ofthe lung tissues of COPD patients to inhaled corticosteroids. A recentpublication of Mercado (Mercado, N., et al., Mol. Pharmacol., 2011,80(6), 1128-1135) demonstrates that silencing p38 MAPK-γ has thepotential to restore sensitivity to corticosteroids. P38 MAPK alpha(Mercado, N. et al., PLoS ONE, 2012, 7(7), e41582, 1-9) and JNK (Papi etal., J. Allergy Clin. Immunol., 2013, 132, 1075-1085) have also beenreported to have roles in regulating corticosteroid insensitivity andArmstrong et al. (JPET, 2011, 338, 732-740) have shown that the mixedp38 isoform inhibitor BIRB-796 and the corticosteroid dexamethasone havesynergistic anti-inflammatory effects on COPD alveolar macrophages.Consequently there may be a benefit for patients in the use of a lessp38 alpha-specific MAP kinase inhibitor for the treatment of COPD andsevere asthma.

Many patients diagnosed with asthma or with COPD continue to suffer fromuncontrolled symptoms and from exacerbations of their medical conditionthat can result in hospitalisation. This occurs despite the use of themost advanced, currently available treatment regimens, comprising ofcombination products of an inhaled corticosteroid and a long actingβ-agonist. Data accumulated over the last decade indicates that afailure to manage effectively the underlying inflammatory component ofthe disease in the lung is the most likely reason that exacerbationsoccur. Given the established efficacy of corticosteroids asanti-inflammatory agents and, in particular, of inhaled corticosteroidsin the treatment of asthma, these findings have provoked intenseinvestigation. Resulting studies have identified that some environmentalinsults invoke corticosteroid-insensitive inflammatory changes inpatients' lungs. An example is the response arising fromvirally-mediated upper respiratory tract infections (URTI), which haveparticular significance in increasing morbidity associated with asthmaand COPD.

Epidemiological investigations have revealed a strong associationbetween viral infections of the upper respiratory tract and asubstantial percentage of the exacerbations suffered by patients alreadydiagnosed with chronic respiratory diseases. Some of the most compellingdata in this regard derives from longitudinal studies of childrensuffering from asthma (Papadopoulos, N. G. et al., Paediatr. Respir.Rev., 2004, 5(3), 255-260). A variety of additional studies support theconclusion that a viral infection can precipitate exacerbations andincrease disease severity. For example, experimental clinical infectionswith rhinovirus have been reported to cause bronchialhyper-responsiveness to histamine in asthmatics that is unresponsive totreatment with corticosteroids (Grunberg, K., et al., Am. J. Respir.Crit. Care Med., 2001, 164(10), 1816-1822). Further evidence derivesfrom the association observed between disease exacerbations in patientswith cystic fibrosis and HRV infections (Wat, D. et al., J. Cyst.Fibros., 2008, 7, 320-328). Also consistent with this body of data isthe finding that respiratory viral infections, including rhinovirus,represent an independent risk factor that correlates negatively with the12 month survival rate in paediatric, lung transplant recipients (Liu,M. et al., Transpl. Infect. Dis., 2009, 11(4), 304-312).

TLR3 is an endosomal pathogen pattern recognition receptor that sensesviral dsRNA that is produced during viral infection. In human bronchialepithelial cells (BEAS2B) the TLR3 pathway is activated in response torhinovirus infection (RV1B and RV39) (Wang et al., J. Immunol., 2009,183, 6989-6997). Inhaled dsRNA and rhinovirus infection evokeneutrophilic exacerbation in allergic mice with established experimentalasthma (Mahmutovic-Persson et al., Allergy, 2014, 69(3), 348-358). In anallergic asthma model, rhinovirus-infected TLR3 knockout micedemonstrated reduced infiltration of neutrophils and macrophages intothe lungs and significantly lower airways inflammation when comparedwith TLR3 positive controls (Wang, Q. et al., PLoS Pathog., 7(5),e1002070). Taken together these observations suggest that activation ofthe TLR3-pathway is likely to play an important role in the developmentof airways inflammation and exacerbations of respiratory disease inresponse to rhinovirus-mediated respiratory tract infections

In human rhinovirus infected cells the activation of TLR3 has been shownto involve the receptor-recruitment and activation of c-Src kinase whichmediates multiple downstream cellular effects. A small number of studieshave appeared that link the activation of cellular Src (Src1 or p60-Src)or Src family kinases to specific responses following infection withviruses. These include a report that adenovirus elicits a PI3 kinasemediated activation of Akt through a c-Src dependent mechanism. Sykkinase activity is reported to be controlled by c-Src as an upstreamkinase in HRV infection (Lau et al., J. Immunol., 2008, 180, 870-880).It has also been suggested that Rhinovirus-39 induced IL-8 production inepithelial cells depends upon Src kinase activation (Bentley, J. K. etal., J. Virol., 2007, 81, 1186-1194). Finally, it has been proposed thatactivation of Src kinase is involved in the induction of mucinproduction by rhinovirus-14 in epithelial cells and sub-mucosal glands(Inoue, D. et al., Respir. Physiol. Neurobiol., 2006, 154(3), 484-499).

It has been disclosed previously that compounds that inhibit p59-HCK areeffective against influenza virus replication (Charron, C. E. et al., WO2011/070369). Certain p38 MAPK inhibitors have also been described asinhibitors of the replication of respiratory syncitial virus (Cass, L.et al., WO 2011/158039).

For the reasons summarised above, compounds designed to treat chronicrespiratory diseases that combine inhibition of c-Src and p59-HCKkinases with the inhibition of p38 MAPKs, are expected to beparticularly efficacious.

In addition to playing key roles in cell signalling events which controlthe activity of pro-inflammatory pathways, kinase enzymes are now alsorecognised to regulate the activity of a range of cellular functions.Among those which have been discussed recently are the maintenance ofDNA integrity (Shilo, Y. Nat. Rev. Cancer, 2003, 3, 155-168) andco-ordination of the complex processes of cell division. An illustrationof recent findings is a publication describing the impact of a set ofinhibitors acting upon the so-called “Olaharsky kinases” on thefrequency of micronucleus formation in vitro (Olaharsky, A. J. et al.,PLoS Comput. Biol., 2009, 5(7), e1000446). Micronucleus formation isimplicated in, or associated with, disruption of mitotic processes andis therefore an undesirable manifestation of potential toxicity.Inhibition of glycogen synthase kinase 3α (GSK3α) was found to be aparticularly significant factor that increases the likelihood of akinase inhibitor promoting micronucleus formation. Recently, inhibitionof the kinase GSK3β with RNAi was also reported to promote micronucleusformation (Tighe, A. et al., BMC Cell Biology, 2007, 8:34).

It may be possible to attenuate the adverse effects arising from druginteractions with Olaharsky kinases, such as GSK3α, by optimisation ofthe dose and/or by changing the route of administration. However, itwould be more advantageous to identify therapeutically useful moleculesthat demonstrate low or undetectable activity against these off-targetenzymes and consequently elicit little or no disruption of mitoticprocesses, as measured in mitosis assays.

It is evident from consideration of the literature cited hereinabovethat there remains a need to identify and develop new p38 MAP kinaseinhibitors that have improved therapeutic potential over currentlyavailable treatments. Desirable compounds are those that exhibit asuperior therapeutic index by exerting, at the least, an equallyefficacious effect as previous agents but, in one or more respects, areless toxic at the relevant therapeutic dose. An objective of the presentinvention therefore, is to provide such a novel compound that inhibitsthe enzyme activity of p38 MAP kinase, for example with certain sub-typespecificities (particularly alpha and gamma), as well as inhibiting theenzyme activity of tyrosine kinases within the Src family (such asp59-HCK and particularly c-Src) thereby possessing goodanti-inflammatory properties, and suitable for use in therapy. Thecompound of the invention exhibits weak or no inhibitory activity ofOlaharsky kinases, such as GSK3α and exhibits weak or no inhibitoryactivity of SYK kinase which contributes to its expected favourablesafety profile.

SUMMARY OF THE INVENTION

According to the invention, there is provided a compound of formula (I):

or a pharmaceutically acceptable salt thereof.

The compound of formula (I) together with its pharmaceuticallyacceptable salts is sometimes referred to herein as “the compound of thepresent invention” or similar.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows an IR spectrum (micro ATR) of a sample of the compound offormula (I), maleate salt, Form 2

FIG. 2 shows a powder XRD pattern of a sample of the compound of formula(I), maleate salt, Form 2

FIG. 3 shows a powder XRD pattern of a sample of the compound of formula(I), maleate salt, Form 1

FIG. 4 shows a DSC curve of a sample of the compound of formula (I),maleate salt, Form 2

FIG. 5 shows a TGA curve of a sample of the compound of formula (I),maleate salt, Form 2

FIG. 6 shows a DVS overlap of a sample of the compound of formula (I),maleate salt, Form 2

FIG. 7 shows a DVS kinetic plot of a sample of the compound of formula(I), maleate salt, Form 2

FIGS. 8A-8F show the results of chemical stability testing on variouscompositions containing the compound of the invention (in free base andmaleate salt forms).

FIG. 9 shows the effect of test compounds on rhinovirus-induced IL-8Release in BEAS2B cells

DETAILED DESCRIPTION OF CERTAIN ILLUSTRATIVE EMBODIMENTS OF THEINVENTION

The compound of formula (I) may be prepared or employed in the form of apharmaceutically acceptable salt, including the therapeutically activenon-toxic acid addition salts that the compound of formula (I) is ableto form. These pharmaceutically acceptable acid addition salts canconveniently be obtained by treating the free base form with suchappropriate acids in a suitable solvent or mixture of solvents.Appropriate acids comprise, for example, inorganic acids such ashydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric,nitric, phosphoric acids and the like; or organic acids such as, forexample, acetic, propanoic, hydroxyacetic, lactic, pyruvic, malonic,succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic,ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic,p-aminosalicylic, pamoic acid and the like. Preferably, the compound offormula (I) is employed in the form of its maleate salt. Conversely saidsalt forms can be converted by treatment with an appropriate base intothe free base form.

The invention provided herein extends to all stereoisomers of thecompound of formula (I). The term stereoisomers as employed hereinrefers to isomeric molecules that have the same molecular formula andsequence of bonded atoms (constitution), but that differ only in thethree-dimensional orientations of their atoms in space.

As employed herein the definition of the compound of formula (I) isintended to include all tautomers of said compounds, and solvates ofsaid compounds (including solvates of salts of said compounds) unlessthe context specifically indicates otherwise. Examples of solvatesinclude hydrates.

The invention provided herein extends to prodrugs of the compound offormula (I), that is to say compounds which break down and/or aremetabolised in vivo to provide an active compound of formula (I).

In a further aspect of the invention there is provided one or moremetabolites of the compound of formula (I), in particular a metabolitethat retains one or more of the therapeutic activities of the compoundof formula (I). A metabolite, as employed herein, is a compound that isproduced in vivo from the metabolism of the compound of formula (I),such as, without limitation, oxidative metabolites and/or metabolitesgenerated, for example, from O-dealkylation.

The compound disclosed includes a compound where the atom specified is anaturally occurring or non-naturally occurring isotope. In oneembodiment the isotope is a stable isotope. Thus the disclosed compoundincludes, for example deuterium containing compounds and the like.

The disclosure also extends to all polymorphic forms of the compoundsherein defined.

A first process for preparing a compound of formula (I) or a protectedderivative thereof comprises reacting a compound of formula (II)

or a protected derivative thereofwherein LG¹ represents a leaving group;with a compound of formula (III)

or a protected derivative thereof;and optionally deprotecting the product to yield a compound of formula(I).

In compounds of formula (II), examples of leaving groups LG include halo(especially Cl, Br) and aryloxy-, especially phenoxy-.

Suitable protecting groups and means for their removal are describedinfra.

Suitable conditions for the reaction of compounds of formula (II) and(III) include treating a mixture of (II) and (III) in a suitable solventsuch as THF, DCM or isopropyl acetate with triethylamine or Hunig's baseand warming the reaction to a temperature such as 40° C.

A second process for preparing a compound of formula (I) comprisesreacting a compound of formula (IV)

or a protected derivative thereof,with a compound of formula (V)

wherein LG² represents leaving group, such as halo and especially Clor a protected derivative thereofand optionally deprotecting the product to yield a compound of formula(I).

Suitable protecting groups and means for their removal are describedinfra.

Suitable conditions for the reaction of compounds of formula (IV) and(V) include those normally employed for the Buchwald reaction i.e.treatment of a solution of (IV) and (V) in a solvent such as 1,4-dioxanewith a palladium source and ligand such as Pd₂(dba)₃ and BINAP and abase such as sodium tert-butoxide or cesium carbonate at elevatedtemperature.

Alternative ligands include diphenylphosphinoferrocene andtriphenylphosphine; alternative palladium sources include palladium (II)acetate and tetrakis(triphenylphosphine)palladium(0); alternative basesinclude lithium bis(trimethylsilyl)amide and potassium phosphate;alternative solvents include THF and toluene. For a wider range ofconditions, see Surry, D. S., Buchwald, S. L. (2008), “Biaryl PhosphaneLigands in Palladium-Catalyzed Amination”, Angew. Chem. Int. Ed., 47,6338-6361, and references therein.

Compounds of formula (II) may be prepared by reaction of a compound offormula (VI)

with a compound of formula LG¹C(═O)LG³ wherein LG³ represents a leavinggroup such as halo and especially Cl.

Suitable conditions for the reaction of a compound of formula (VI) witha compound of formula LG¹C(═O)LG³ where LG¹ is PhO and LG³ is Clcomprise treatment of a mixture of a solution of compound of formula(VI) in a solvent such as isopropyl acetate and an aqueous solution ofan inorganic base such as sodium carbonate with phenyl chloroformate.

Compounds of formula (VI) are known or may be prepared by methods knownto persons skilled in the art.

A first process for preparing a compound of formula (III) comprisesreducing a compound of formula (VII)

Suitable conditions for the reduction of a compound of formula (VII)include treatment with hydrogen gas over platinum on carbon catalyst.This reaction may be carried out at elevated pressure in a solvent suchas THF acidified with acetic acid. Alternatively it may be performed ina solvent such as DCM/MeOH under flow conditions using an H-cubehydrogenator.

A second process for preparing a compound of formula (III) comprisesdeprotecting a compound of formula (VIII)

wherein P₁ represents an amine protecting group.

Suitable protecting groups and means for their removal are describedinfra. A most suitable protecting group is Boc which can be removed bytreatment with acid such as TFA or HCl.

A first process for preparing a compound of formula (VII) comprisesreacting a compound of formula (IX)

with a compound of formula (X)

wherein Hal represents halogen, especially Cl.

Suitable conditions for the reaction of compounds of formula (IX) and(X) include those mentioned above for the reaction of compounds offormula (IV) and (V).

A second process for preparing a compound of formula (VII) comprisesreacting a compound of formula (XI)

wherein Hal represents halogen, especially Clwith a compound of formula (XII)

Suitable conditions for the reaction of compounds of formula (XI) and(XII) include treatment of a solution of (XI) and (XII) in a solventsuch as 1,4-dioxane with a palladium source and ligand such as Pd₂(dba)₃and BINAP and a base such as sodium tert-butoxide or cesium carbonate atelevated temperature.

A first process for preparing a compound of formula (VIII) comprisesreacting a compound of formula (XIII)

with a compound of formula (X)

wherein Hal represents halogen, especially Cl.

Suitable conditions for the reaction of compounds of formula (XIII) and(X) are the same as those described above for the reaction of compoundsof formula (IX) and (X).

A second process for preparing compounds of formula (VIII) comprisesreacting a compound of formula (XIV)

wherein Hal represents halogen, especially Clwith a compound of formula (XII)

Suitable conditions for the reaction of compounds of formula (XIV) and(XII) are the same as those described above for the reaction ofcompounds of formula (XI) and (XII).

Compounds of formula (IX) may be prepared as shown in the scheme below:

The reagents of this process are known compounds. Mitsunobu conditionsinclude treatment of a mixture of a phenol and an alcohol withtriphenylphosphine and diisopropylazodicarboxylate in a solvent such asTHF. For a wider range of conditions, see Swamy, K. C.; Kumar, N. N.;Balaraman, E.; Kumar, K. V. (2009). “Mitsunobu and Related Reactions:Advances and Applications” Chemical Reviews 109 (6): 2551-2651, andreferences therein.

Compounds of formula (XI) may be prepared as shown in the scheme below:

The reagents of this process are known compounds. Mitsunobu conditionsinclude those given above.

Compounds of formula (XIII) may be prepared as shown in the schemebelow:

wherein LG⁴ is a leaving group such as halo, especially Cl.

The reagents of this process are known compounds. Alkylation conditionsinclude treatment of a mixture of a phenol and an alkyl halide with abase such as cesium or potassium carbonate in a solvent such asacetonitrile or DMF optionally at elevated temperature.

Compounds of formula (XIV) may be prepared as shown in the scheme below:

wherein LG⁵ is a leaving group such as those mentioned above for LG⁴.

The reagents of this process are known compounds. Alkylation conditionsinclude those given above.

Compounds of formula (IV), (V), (VI), (X) and (XII) are either known ormay be prepared by methods known to the skilled person. In respect ofcompound of formula (IV) see, for example, WO2010/067131, andspecifically the compound structure referred to as “Intermediate A”. Inrespect of compound of formula (VI) see, for example, WO00/043384, andspecifically compound of formula LXVII.

An apparently stable crystalline unsolvated form of the free base formof the compound of the invention may be obtained by recrystallisationfrom solution (preferably hot, e.g. reflux temperature) in acetonitrile.In case another form is produced, this form may be obtained by slurryingin acetonitrile.

As noted above, the maleate salt is a form of the compound of theinvention of particular interest. The maleate salt may be prepared bytreating the free base form of the compound of the invention with maleicacid in a suitable solvent.

In a preferred process, the maleate salt is prepared by treating asolution of the compound of the invention in 2-butanone with a solutionof maleic acid in 2-butanone. Crystallisation is allowed to occur, whichmay be assisted with seeding. The maleate salt as its Form 2 crystallinepolymorph is prepared this way. The Form 2 crystalline polymorph mayalso be obtained by cooling a hot solution of the maleate salt of thecompound of the invention in 2-butanone, e.g. from 50° C. to roomtemperature. Crystallisation is allowed to occur, which may be assistedwith seeding.

The Form 2 crystalline polymorph of the maleate salt of the compound ofthe invention is characterised by having peak positions in a powder XRDpattern at 4.2, 8.4, 8.7, 11.0, 11.5, 12.6, 14.4, 14.9, 16.0, 17.0,17.4, 18.8, 19.5, 20.2, 21.7, 22.4, 23.8, 25.8 and 26.3 (±0.2) degrees2-theta (see FIG. 2). The peaks (the doublet) at 8.4 and 8.7 (±0.2)degrees 2-theta are especially characteristic for the Form 2 crystallinepolymorph since peaks in these positions are absent in the XRD patternof the Form 1 crystalline polymorph.

The Form 2 crystalline polymorph has a high melting point (approx 199°C.) with a plate like morphology.

Another crystalline form of the maleate salt of the compound of theinvention was identified following recrystallisation from THF which hasless favourable properties than those of Form 2. It has needle likemorphology and a lower melting point, approx 148° C. This crystallineform is referred to as Form 1.

The Form 1 crystalline polymorph of the maleate salt of the compound ofthe invention is characterised by having peak positions in a powder XRDpattern at 3.8, 6.3, 7.8, 9.3, 9.9, 10.7, 11.2, 12.7, 15.4, 16.5, 17.9,19.2 and 19.6 (±0.2) degrees (see FIG. 3). The peaks at 6.3, 7.8 and 9.9(±0.2) degrees 2-theta are especially characteristic for the Form 1crystalline polymorph since peaks in these positions are absent in theXRD pattern of the Form 2 crystalline polymorph.

Thus the Form 2 polymorph is characterised by having an XRD diffractionpattern containing 10, 11, 12, 13, 14, 15, 16, 17, 18 or more preferably19 peak positions selected from 4.2, 8.4, 8.7, 11.0, 11.5, 12.6, 14.4,14.9, 16.0, 17.0, 17.4, 18.8, 19.5, 20.2, 21.7, 22.4, 23.8, 25.8 and26.3 (±0.2) degrees 2-theta preferably including peaks at 8.4 and 8.7(±0.2) degrees 2-theta and not containing peaks at 6.3, 7.8 and 9.9(±0.2) degrees 2-theta.

In relation to FIGS. 2 and 3, it will be understood that intensityvariations in XRD patterns can occur due to processes which influenceintensities, such as the processing history of the sample.

Salts of the compound of the invention which are crystalline but oflesser interest than the maleate salt include hydrobromide, phosphate,tartrate, fumarate and mesylate salts.

Protecting groups may be required to protect chemically sensitive groupsduring one or more of the reactions described above, to ensure that theprocess is efficient. Thus if desired or necessary, intermediatecompounds (including compounds of formula (II) to (V) as highlightedabove as well as compounds of formula (VI) to (XIV)) may be protected bythe use of conventional protecting groups. Protecting groups and meansfor their removal are described in “Protective Groups in OrganicSynthesis”, by Theodora W. Greene and Peter G. M. Wuts, published byJohn Wiley & Sons Inc; 4^(th) Rev Ed., 2006, ISBN-10: 0471697540. Thusexemplary amine protecting groups include Boc which may be removed byTFA and exemplary alcohol protecting groups are THP which may be removedby HCl.

Compounds of formula (III) (together with derivatives thereof in whichthe amino group is protected, such as the compound of formula (VIII))and the compound of formula (VII) are novel. These novel compounds,together with their salts (including pharmaceutically acceptable salts)are claimed as aspects of the invention.

Hence, the invention extends to a compound of formula (III)

or a derivative thereof in which the amino group is protected, or a saltthereof; for example a compound of formula (VIII)

wherein P₁ represents an amine protecting group;or a salt thereof; as well as a compound of formula (VII)

or a salt thereof.

The compound of formula (I) is a p38 MAP kinase inhibitor (especially aninhibitor of the alpha subtype) and in one aspect the compound of thepresent invention is provided for use as a medicament e.g. in thetreatment of inflammatory diseases, for example COPD and/or asthma.

The compound of formula (I) is expected to be potent in vivo.

Typically, the prior art compounds developed to date have been intendedfor oral administration. This strategy involves optimizing thepharmacokinetic profile of drug substances in order to achieve anadequate duration of action. In this manner a sufficiently high drugconcentration is established and maintained between doses to providesustained clinical benefit. The inevitable consequence of this approachis that all bodily tissues, and especially the liver and the gut, arelikely to be exposed to supra-therapeutically active concentrations ofthe drug, whether or not they are adversely affected by the diseasebeing treated.

An alternative strategy is to design treatment paradigms in which thedrug is dosed directly to the inflamed organ, that is, to exploittopical administration. Whilst this approach is not suitable fortreating all chronic inflammatory diseases, it has been exploited inlung disorders, such as asthma and COPD; in skin diseases, for exampleagainst atopic dermatitis and psoriasis; for nasal conditions, typifiedby allergic rhinitis; and in gastrointestinal diseases, such asulcerative colitis, IBD and Crohn's disease and inflammatory diseases ofthe eye, such as uveitis.

In topical therapy, one way in which efficacy can be achieved is by theuse of a drug that has a sustained duration of action and is retained inthe relevant organ, thereby minimizing the risk of systemic toxicity.Alternatively, in some cases, a formulation can be developed thatgenerates a “reservoir” of the active drug which is available to sustainits desired effects. The first approach is exemplified by theanticholinergic drug tiotropium (Spiriva). This compound is administeredtopically to the lung as a treatment for COPD, and has an exceptionallyhigh affinity for its target receptor resulting in a very slow off rateand consequently displays a sustained duration of action.

In one aspect of the disclosure of the compound of formula (I) it isparticularly suitable for topical delivery, such as topical delivery tothe lungs, in particular for the treatment of respiratory disease, forexample chronic respiratory diseases such as COPD and/or asthma.

In one embodiment the compound of formula (I) is suitable forsensitizing patients to treatment with a corticosteroid who have becomerefractory to such treatment regimens.

The compound of formula (I) may have antiviral properties, for examplethe ability to prevent the infection of cells (such as respiratoryepithelial cells) with a picornavirus, in particular a rhinovirus,influenza or respiratory syncytial virus.

Thus the compounds are thought to be antiviral agents, in particularsuitable for the prevention, treatment or amelioration of picornavirusinfections, such as rhinovirus infection, influenza or respiratorysyncytial virus.

In one embodiment the compound of formula (I) is able to reduceinflammation induced by viral infection, such as rhinovirus infectionand in particular viral infections that result in the release ofcytokines such as IL-8, especially in vivo. This activity may, forexample, be tested in vitro employing a rhinovirus induced IL-8 assay asdescribed in the Examples herein.

In one embodiment the compound of formula (I) is able to reduce ICAM1expression induced by rhinovirus, especially in vivo. ICAM1 is thereceptor mechanism used by so-called major groove rhinovirus serotypesto infect cells. This activity may be measured, for example by a methoddescribed in the Examples herein.

It is expected that the above properties render the compound of formula(I) particularly suitable for use in the treatment (includingprophylaxis) of exacerbations of inflammatory diseases, in particularviral exacerbations, or in the treatment of viral infections, inpatients with one or more chronic conditions such as congestive heartfailure, COPD, asthma, diabetes, cancer and/or in immunosuppressedpatients, for example post-organ transplant. Such use may be incombination with anti-viral agents such as zanamivir, oseltamivir (forexample oseltamivir phosphate) peramivir or laninamivir.

In general, the compound of formula (I) may be useful in the treatmentof one or more conditions having an inflammatory component which,suitably, may be treated by topical or local therapy.

In particular, the compound of formula (I) may be useful in thetreatment of one or more respiratory disorders including COPD (includingchronic bronchitis and emphysema), asthma, paediatric asthma, cysticfibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis,rhinitis and sinusitis, especially asthma, or COPD (including chronicbronchitis and emphysema).

Thus the compound of formula (I) may be useful in the treatment of lunginflammation (and symptoms thereof) in subjects suffering from cysticfibrosis.

The compound of formula (I) may be useful in the treatment of eyediseases or disorders including keratoconjunctivitis sicca (dry eye),allergic conjunctivitis, conjunctivitis, diabetic retinopathy, macularoedema (including wet macular oedema and dry macular oedema),post-operative cataract inflammation or, particularly, uveitis(including posterior, anterior and pan uveitis).

The compound of formula (I) may be useful in the treatment of skindiseases or disorders including allergic dermatitis, contact dermatitis,atopic dermatitis or psoriasis.

The compound of formula (I) may be useful in the treatment ofgastrointestinal diseases or disorders including ulcerative colitis, IBDor Crohn's disease.

The compound of formula (I) may be useful in the treatment of jointdiseases or disorders including rheumatoid arthritis or osteoarthritisand particularly inflamed joints secondary to such conditions.

The compound of formula (I) may be useful in the treatment of cancersincluding cancer of the stomach and in the inhibition of the growth andmetastasis of tumours including lung cancers such as non-small cell lungcarcinoma, gastric carcinoma, colorectal carcinomas and malignantmelanoma.

It is also expected that the compound of formula (I) may be useful inthe treatment of certain other conditions including periodontitis,gingivitis and pharyngitis.

Compound of formula (I) may also re-sensitise the patient's condition totreatment with a corticosteroid, when the patient's condition has becomerefractory to the same.

Furthermore, the present invention provides a pharmaceutical compositioncomprising a compound according to the disclosure optionally incombination with one or more pharmaceutically acceptable diluents orcarriers.

Diluents and carriers may include those suitable for parenteral, oral,topical, mucosal and rectal administration.

The present invention also provides a process for preparing such apharmaceutical composition (for example a pharmaceutical composition forparenteral, oral, topical, mucosal or rectal administration), saidprocess comprising mixing the ingredients.

As mentioned above, such compositions may be prepared e.g. forparenteral, subcutaneous, intramuscular, intravenous, intra-articular orperi-articular administration, particularly in the form of liquidsolutions or suspensions; for oral administration, particularly in theform of tablets or capsules or in the form of liquid solutions orsuspensions; for topical e.g. pulmonary or intranasal administration,particularly in the form of powders, aqueous solutions or suspensions,nasal drops or aqueous or non-aqueous aerosols, and for transdermaladministration e.g. patches, creams, ointments; for mucosaladministration e.g. to buccal, sublingual or vaginal mucosa, and forrectal administration e.g. in the form of a suppository, cream, ointmentor foam.

The compositions may conveniently be administered in unit or multi-dosedosage forms and may be prepared by any of the methods well-known in thepharmaceutical art, for example as described in Remington'sPharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa.,(1985). Formulations for parenteral administration may contain asexcipients sterile water or saline, alkylene glycols such as propyleneglycol, polyalkylene glycols such as polyethylene glycol, oils ofvegetable origin, hydrogenated naphthalenes and the like. Formulationsfor nasal administration may be solid and may contain excipients, forexample, lactose or dextran, or may be aqueous or oily solutions orsuspensions for use in the form of nasal drops or metered sprays. Forbuccal administration typical excipients include sugars, calciumstearate, magnesium stearate, pregelatinated starch, and the like.

Compositions suitable for oral administration may comprise one or morephysiologically compatible carriers and/or excipients and may be insolid or liquid form. Tablets and capsules may be prepared with bindingagents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, orpoly-vinylpyrollidone; fillers, such as lactose, sucrose, corn starch,calcium phosphate, sorbitol, or glycine; lubricants, such as magnesiumstearate, talc, polyethylene glycol, or silica; and surfactants, such assodium lauryl sulfate. Liquid compositions may contain conventionaladditives such as suspending agents, for example sorbitol syrup, methylcellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or ediblefats; emulsifying agents such as lecithin, or acacia; vegetable oilssuch as almond oil, coconut oil, cod liver oil, or peanut oil;preservatives such as butylated hydroxyanisole (BHA) and butylatedhydroxytoluene (BHT). Liquid compositions may be encapsulated in, forexample, gelatin to provide a unit dosage form.

Solid oral dosage forms include tablets, two-piece hard shell capsulesand soft elastic gelatin (SEG) capsules.

A dry shell formulation typically comprises of about 40% to 60% w/wconcentration of gelatin, about a 20% to 30% concentration ofplasticizer (such as glycerin, sorbitol or propylene glycol) and about a30% to 40% concentration of water. Other materials such aspreservatives, dyes, opacifiers and flavours also may be present. Theliquid fill material comprises a solid drug that has been dissolved,solubilized or dispersed (with suspending agents such as beeswax,hydrogenated castor oil or polyethylene glycol 4000) or a liquid drug invehicles or combinations of vehicles such as mineral oil, vegetableoils, triglycerides, glycols, polyols and surface-active agents.

Suitably a compound of formula (I) is administered topically to thelung, eye or bowel. Hence we provide according to the invention apharmaceutical composition comprising a compound of the presentinvention optionally in combination with one or more topicallyacceptable diluents or carriers.

Topical administration to the lung may be achieved by use of an aerosolformulation. Aerosol formulations typically comprise the activeingredient suspended or dissolved in a suitable aerosol propellant, suchas a chlorofluorocarbon (CFC) or a hydrofluorocarbon (HFC). Suitable CFCpropellants include trichloromonofluoromethane (propellant 11),dichlorotetrafluoromethane (propellant 114), and dichlorodifluoromethane(propellant 12). Suitable HFC propellants include tetrafluoroethane(HFC-134a) and heptafluoropropane (HFC-227). The propellant typicallycomprises 40%-99.5% e.g. 40%-90% by weight of the total inhalationcomposition. The formulation may comprise excipients includingco-solvents (e.g. ethanol) and surfactants (e.g. lecithin, sorbitantrioleate and the like). Other possible excipients include polyethyleneglycol, polyvinylpyrrolidone, glycerine and the like. Aerosolformulations are packaged in canisters and a suitable dose is deliveredby means of a metering valve (e.g. as supplied by Bespak, Valois or 3Mor alternatively by Aptar, Coster or Van).

Topical administration to the lung may also be achieved by use of anon-pressurised formulation such as an aqueous solution or suspension.These may be administered by means of a nebuliser e.g. one that can behand-held and portable or for home or hospital use (ie non-portable).The formulation may comprise excipients such as water, buffers, tonicityadjusting agents, pH adjusting agents, surfactants and co-solvents.Suspension liquid and aerosol formulations (whether pressurised orunpressurised) will typically contain the compound of the invention infinely divided form, for example with a D₅₀ of 0.5-10 μm e.g. around 1-5μm. Particle size distributions may be represented using D₁₀, D₅₀ andD₉₀ values. The D₅₀ median value of particle size distributions isdefined as the particle size in microns that divides the distribution inhalf. The measurement derived from laser diffraction is more accuratelydescribed as a volume distribution, and consequently the D₅₀ valueobtained using this procedure is more meaningfully referred to as a Dv₅₀value (median for a volume distribution). As used herein Dv values referto particle size distributions measured using laser diffraction.Similarly, D₁₀ and D₉₀ values, used in the context of laser diffraction,are taken to mean Dv₁₀ and Dv₉₀ values and refer to the particle sizewhereby 10% of the distribution lies below the D₁₀ value, and 90% of thedistribution lies below the D₉₀ value, respectively.

Topical administration to the lung may also be achieved by use of adry-powder formulation. A dry powder formulation will contain thecompound of the disclosure in finely divided form, typically with a massmean diameter (MMAD) of 1-10 μm or a D₅₀ of 0.5-10 μm e.g. around 1-5μm. Powders of the compound of the invention in finely divided form maybe prepared by a micronization process or similar size reductionprocess. Micronization may be performed using a jet mill such as thosemanufactured by Hosokawa Alpine. The resultant particle sizedistribution may be measured using laser diffraction (e.g. with aMalvern Mastersizer 2000S instrument). The formulation will typicallycontain a topically acceptable diluent such as lactose, glucose ormannitol (preferably lactose), usually of comparatively large particlesize e.g. a mass mean diameter (MMAD) of 50 μm or more, e.g. 100 μm ormore or a D₅₀ of 40-150 μm. As used herein, the term “lactose” refers toa lactose-containing component, including α-lactose monohydrate,β-lactose monohydrate, α-lactose anhydrous, β-lactose anhydrous andamorphous lactose. Lactose components may be processed by micronization,sieving, milling, compression, agglomeration or spray drying.Commercially available forms of lactose in various forms are alsoencompassed, for example Lactohale® (inhalation grade lactose; DFEPharma), InhaLac®70 (sieved lactose for dry powder inhaler; Meggle),Pharmatose® (DFE Pharma) and Respitose® (sieved inhalation gradelactose; DFE Pharma) products. In one embodiment, the lactose componentis selected from the group consisting of α-lactose monohydrate,α-lactose anhydrous and amorphous lactose. Preferably, the lactose isα-lactose monohydrate.

Dry powder formulations may also contain other excipients. Thus in oneembodiment a dry powder formulation according the present disclosurecomprises magnesium or calcium stearate. Such formulations may havesuperior chemical and/or physical stability especially when suchformulations also contain lactose.

A dry powder formulation is typically delivered using a dry powderinhaler (DPI) device. Example dry powder delivery systems includeSPINHALER®, DISKHALER®, TURBOHALER®, DISKUS®, SKYEHALER®, ACCUHALER® andCLICKHALER®. Further examples of dry powder delivery systems includeECLIPSE, NEXT, ROTAHALER, HANDIHALER, AEROLISER, CYCLOHALER,BREEZHALER/NEOHALER, MONODOSE, FLOWCAPS, TWINCAPS, X-CAPS, TURBOSPIN,ELPENHALER, MIATHALER, TWISTHALER, NOVOLIZER, PRESSAIR, ELLIPTA, ORIELdry powder inhaler, MICRODOSE, PULVINAL, EASYHALER, ULTRAHALER, TAIFUN,PULMOJET, OMNIHALER, GYROHALER, TAPER, CONIX, XCELOVAIR and PROHALER.

In one embodiment a compound of the present invention is provided as amicronized dry powder formulation, for example comprising lactose of asuitable grade.

Thus, as an aspect of the invention there is provided a pharmaceuticalcomposition comprising a compound of the invention in particulate formin combination with particulate lactose, said composition optionallycomprising magnesium stearate.

In one embodiment a compound of the present invention is provided as amicronized dry powder formulation, comprising lactose of a suitablegrade and magnesium stearate, filled into a device such as DISKUS.Suitably, such a device is a multidose device, for example theformulation is filled into blisters for use in a multi-unit dose devicesuch as DISKUS.

In another embodiment a compound of the present invention is provided asa micronized dry powder formulation, for example comprising lactose of asuitable grade, filled into hard shell capsules for use in a single dosedevice such as AEROLISER.

In another embodiment a compound of the present invention is provided asa micronized dry powder formulation, comprising lactose of a suitablegrade and magnesium stearate, filled into hard shell capsules for use ina single dose device such as AEROLISER.

In another embodiment a compound of the present invention is provided asa fine powder for use in an inhalation dosage form wherein the powder isin fine particles with a D₅₀ of 0.5-10 μm e.g. around 1-5 μm, that havebeen produced by a size reduction process other than jet millmicronisation e.g. spray drying, spray freezing, microfluidisation, highpressure homogenisation, super critical fluid crystallisation,ultrasonic crystallisation or combinations of these methods thereof, orother suitable particle formation methods known in the art that are usedto produce fine particles with an aerodynamic particle size of 0.5-10μm. The resultant particle size distribution may be measured using laserdiffraction (e.g. with a Malvern Mastersizer 2000S instrument). Theparticles may either comprise the compound alone or in combination withsuitable other excipients that may aid the processing. The resultantfine particles may form the final formulation for delivery to humans ormay optionally be further formulated with other suitable excipients tofacilitate delivery in an acceptable dosage form.

The compound of the invention may also be administered rectally, forexample in the form of suppositories or enemas, which include aqueous oroily solutions as well as suspensions and emulsions and foams. Suchcompositions are prepared following standard procedures, well known bythose skilled in the art. For example, suppositories can be prepared bymixing the active ingredient with a conventional suppository base suchas cocoa butter or other glycerides. In this case, the drug is mixedwith a suitable non-irritating excipient which is solid at ordinarytemperatures but liquid at the rectal temperature and will thereforemelt in the rectum to release the drug. Such materials are cocoa butterand polyethylene glycols.

Generally, for compositions intended to be administered topically to theeye in the form of eye drops or eye ointments, the total amount of thecompound of the present invention will be about 0.0001 to less than 4.0%(w/w).

Preferably, for topical ocular administration, the compositionsadministered according to the present invention will be formulated assolutions, suspensions, emulsions and other dosage forms. Aqueoussolutions are generally preferred, based on ease of formulation, as wellas a patients ability to administer such compositions easily by means ofinstilling one to two drops of the solutions in the affected eyes.However, the compositions may also be suspensions, viscous orsemi-viscous gels, or other types of solid or semi-solid compositions.Suspensions may be preferred for compounds that are sparingly soluble inwater.

An alternative for administration to the eye is intravitreal injectionof a solution or suspension of the compound of the present invention. Inaddition, the compound of the present invention may also be introducedby means of ocular implants or inserts.

The compositions administered according to the present invention mayalso include various other ingredients, including, but not limited to,tonicity agents, buffers, surfactants, stabilizing polymer,preservatives, co-solvents and viscosity building agents. Suitablepharmaceutical compositions of the present invention include a compoundof the invention formulated with a tonicity agent and a buffer. Thepharmaceutical compositions of the present invention may furtheroptionally include a surfactant and/or a palliative agent and/or astabilizing polymer.

Various tonicity agents may be employed to adjust the tonicity of thecomposition, preferably to that of natural tears for ophthalmiccompositions. For example, sodium chloride, potassium chloride,magnesium chloride, calcium chloride, simple sugars such as dextrose,fructose, galactose, and/or simply polyols such as the sugar alcoholsmannitol, sorbitol, xylitol, lactitol, isomaltitol, maltitol, andhydrogenated starch hydrolysates may be added to the composition toapproximate physiological tonicity. Such an amount of tonicity agentwill vary, depending on the particular agent to be added. In general,however, the compositions will have a tonicity agent in an amountsufficient to cause the final composition to have an ophthalmicallyacceptable osmolality (generally about 150-450 mOsm, preferably 250-350mOsm and most preferably at approximately 290 mOsm). In general, thetonicity agents of the invention will be present in the range of 2 to 4%w/w. Preferred tonicity agents of the invention include the simplesugars or the sugar alcohols, such as D-mannitol.

An appropriate buffer system (e.g. sodium phosphate, sodium acetate,sodium citrate, sodium borate or boric acid) may be added to thecompositions to prevent pH drift under storage conditions. Theparticular concentration will vary, depending on the agent employed.Preferably however, the buffer will be chosen to maintain a target pHwithin the range of pH 5 to 8, and more preferably to a target pH of pH5 to 7.

Surfactants may optionally be employed to deliver higher concentrationsof compound of the present invention. The surfactants function tosolubilise the compound and stabilise colloid dispersion, such asmicellar solution, microemulsion, emulsion and suspension. Examples ofsurfactants which may optionally be used include polysorbate, poloxamer,polyosyl 40 stearate, polyoxyl castor oil, tyloxapol, Triton, andsorbitan monolaurate. Preferred surfactants to be employed in theinvention have a hydrophile/lipophile/balance “HLB” in the range of 12.4to 13.2 and are acceptable for ophthalmic use, such as TritonX114 andtyloxapol.

Additional agents that may be added to the ophthalmic compositions ofcompounds the present invention are demulcents which function as astabilising polymer. The stabilizing polymer should be an ionic/chargedexample with precedence for topical ocular use, more specifically, apolymer that carries negative charge on its surface that can exhibit azeta-potential of (−)10-50 mV for physical stability and capable ofmaking a dispersion in water (i.e. water soluble). A preferredstabilising polymer of the invention would be polyelectrolyte, orpolyelectrolytes if more than one, from the family of cross-linkedpolyacrylates, such as carbomers and Pemulen®, specifically Carbomer974p (polyacrylic acid), at 0.1-0.5% w/w.

Other compounds may also be added to the ophthalmic compositions of thecompound of the present invention to increase the viscosity of thecarrier. Examples of viscosity enhancing agents include, but are notlimited to: polysaccharides, such as hyaluronic acid and its salts,chondroitin sulfate and its salts, dextrans, various polymers of thecellulose family; vinyl polymers; and acrylic acid polymers.

Topical ophthalmic products are typically packaged in multidose form.Preservatives are thus required to prevent microbial contaminationduring use. Suitable preservatives include: benzalkonium chloride,chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben,phenylethyl alcohol, edentate disodium, sorbic acid, polyquaternium-1,or other agents known to those skilled in the art. Such preservativesare typically employed at a level of from 0.001 to 1.0% w/v. Unit dosecompositions of the present invention will be sterile, but typicallyunpreserved. Such compositions, therefore, generally will not containpreservatives.

The medical practitioner, or other skilled person, will be able todetermine a suitable dosage for the compound of the present invention,and hence the amount of the compound of the invention that should beincluded in any particular pharmaceutical formulation (whether in unitdosage form or otherwise).

A compound of formula (I) has therapeutic activity. Thus, in a furtheraspect, the present invention provides a compound as described hereinfor use in the treatment of one or more of the above mentionedconditions.

In a further aspect, the present invention provides use of a compound asdescribed herein for the manufacture of a medicament for the treatmentof one or more of the above mentioned conditions.

In a further aspect, the present invention provides a method oftreatment of one or more of the above mentioned conditions whichcomprises administering to a subject an effective amount of a compoundof the present invention or a pharmaceutical composition comprising thecompound.

The word “treatment” is intended to embrace prophylaxis as well astherapeutic treatment. Treatment of conditions or disorders alsoembraces treatment of exacerbations thereof.

A compound of the present invention may also be administered incombination with one or more other active ingredients e.g. activeingredients suitable for treating the above mentioned conditions.

For example, possible combinations for treatment of respiratorydisorders include combinations with steroids (e.g. budesonide,beclomethasone dipropionate, fluticasone propionate, mometasone furoate,fluticasone furoate, ciclesonide), beta agonists (e.g. terbutaline,salbutamol, salmeterol, formoterol, vilanterol, olodaterol, indacaterol,reproterol, fenoterol), xanthines (e.g. theophylline), anticholinergicsor muscarinic antagonists (e.g. ipratropium, tiotropium, aclidinium,umeclidinium or glycopyrronium for example as the bromide salt), PI3kinase inhibitors and anti-viral agents (e.g. zanamivir, oseltamivir,for example as the phosphate, peramivir and laninamivir).

In one embodiment there is provided a compound of the invention for useas a medicament to be administered in combination with one or morefurther active ingredients e.g. selected from corticosteroids, betaagonists, xanthines, muscarinic antagonists and PI3 kinase inhibitors.Suitably the beta agonist is a beta2 agonist.

In one embodiment the compound of the disclosure is administered byinhalation and a corticosteroid is administered orally or by inhalationeither in combination or separately.

In one embodiment the compound of the disclosure is administered byinhalation and a beta2 agonist is administered orally or by inhalationeither in combination or separately.

In one embodiment the compound of the disclosure is administered byinhalation and a muscarinic antagonist is administered orally or byinhalation either in combination or separately.

In one embodiment the compound of the disclosure is administered byinhalation either in combination or separately with one or more of acorticosteroid, a beta2 agonist and a muscarinic antagonist, alladministered either orally or by inhalation.

Further, for the treatment of gastrointestinal disorders (such asCrohn's disease or ulcerative colitis), possible combinations includecombinations with, for example, one or more agents selected from thelist comprising:

-   -   5-aminosalicylic acid, or a prodrug thereof (such as        sulfasalazine, olsalazine or bisalazide);    -   corticosteroids (e.g. prednisolone, methylprednisolone, or        budesonide);    -   immunosuppressants (e.g. cyclosporin, tacrolimus, methotrexate,        azathioprine or 6-mercaptopurine);    -   anti-TNFα antibodies (e.g. infliximab, adalimumab, certolizumab        pegol or golimumab);

anti-IL12/IL23 antibodies (e.g. ustekinumab) or small molecule IL12/IL23inhibitors (e.g., apilimod);

-   -   Anti-α4β7 antibodies (e.g. vedolizumab);    -   MAdCAM-1 blockers (e.g. βF-00547659);    -   antibodies against the cell adhesion molecule α4-integrin (e.g.        natalizumab);

antibodies against the IL2 receptor a subunit (e.g. daclizumab orbasiliximab);

-   -   JAK3 inhibitors (e.g. tofacitinib or R348);    -   Syk inhibitors and prodrugs thereof (e.g. fostamatinib and        R-406);    -   Phosphodiesterase-4 inhibitors (e.g. tetomilast);    -   HMPL-004;    -   probiotics;    -   Dersalazine;    -   semapimod/CPSI-2364; and    -   protein kinase C inhibitors (e.g. AEB-071).

For the treatment of eye disorders (such as keratoconjunctivitis siccaor uveitis), possible combinations include combinations with, forexample, one or more agents selected from the list comprising:

-   -   corticosteroids (e.g. dexamethasone, prednisolone, triamcinolone        acetonide, difluprednate or fluocinolone acetonide);    -   immunosuppressants (e.g. cyclosporin, voclosporin, azathioprine,        methotrexate, mycophenolate mofetil or tacrolimus);    -   anti-TNFα antibodies (e.g. infliximab, adalimumab, certolizumab        pegol, ESBA-105 or golimumab);    -   anti-IL-17A antibodies (e.g. secukinumab);    -   mTOR inhibitors (e.g. sirolimus);    -   VGX-1027;    -   JAK3 inhibitors (e.g. tofacitinib or R348); and    -   protein kinase C inhibitors (e.g. AEB-071).

Hence another aspect of the invention provides a compound of formula (I)in combination with one or more further active ingredients, for exampleone or more active ingredients described above.

Similarly, another aspect of the invention provides a combinationproduct comprising:

(A) a compound of the present invention; and(B) one or more other therapeutic agents,wherein each of components (A) and (B) is formulated in admixture with apharmaceutically-acceptable adjuvant, diluent or carrier.

In this aspect of the invention, the combination product may be either asingle (combination) pharmaceutical formulation or a kit of parts.

Thus, this aspect of the invention encompasses a pharmaceuticalformulation including a compound of the present invention and anothertherapeutic agent, in admixture with a pharmaceutically acceptableadjuvant, diluent or carrier (which formulation is hereinafter referredto as a “combined preparation”).

It also encompasses a kit of parts comprising components:

-   (i) a pharmaceutical formulation including a compound of the present    invention in admixture with a pharmaceutically acceptable adjuvant,    diluent or carrier; and-   (ii) a pharmaceutical formulation including one or more other    therapeutic agents, in admixture with a pharmaceutically-acceptable    adjuvant, diluent or carrier,    which components (i) and (ii) are each provided in a form that is    suitable for administration in conjunction with the other.

Component (i) of the kit of parts is thus component (A) above inadmixture with a pharmaceutically acceptable adjuvant, diluent orcarrier. Similarly, component (ii) is component (B) above in admixturewith a pharmaceutically acceptable adjuvant, diluent or carrier.

The one or more other therapeutic agents (i.e. component (B) above) maybe, for example, any of the agents mentioned above in connection withthe treatment of respiratory, gastrointestinal and eye disorders.

If component (B) is more than one further therapeutic agent, thesefurther therapeutic agents can be formulated with each other orformulated with component (A) or they may be formulated separately.

In one embodiment component (B) is one other therapeutic agent. Inanother embodiment component (B) is two other therapeutic agents.

The combination product (either a combined preparation or kit of parts)of this aspect of the invention may be used in the treatment orprevention of an inflammatory disease e.g. the inflammatory diseasesmentioned above, such as:

-   -   respiratory disorders including COPD (including chronic        bronchitis and emphysema), asthma, paediatric asthma, cystic        fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic        rhinitis, rhinitis and sinusitis, especially asthma, or COPD        (including chronic bronchitis and emphysema);    -   eye diseases or disorders including allergic conjunctivitis,        conjunctivitis, keratoconjunctivitis sicca (dry eye), glaucoma,        diabetic retinopathy, macular oedema (including diabetic macular        oedema), central retinal vein occlusion (CRVO), dry and/or wet        age related macular degeneration (AMD), post-operative cataract        inflammation or, particularly, uveitis (including posterior,        anterior and pan uveitis), corneal graft and limbal cell        transplant rejection;    -   skin diseases or disorders including allergic dermatitis,        contact dermatitis, atopic dermatitis or psoriasis; and    -   gastrointestinal diseases or disorders including gluten        sensitive enteropathy (coeliac disease), eosinophilic        esophagitis, intestinal graft versus host disease or,        particularly, ulcerative colitis or Crohn's disease.

The aspects of the invention described herein (e.g. the above-mentionedcompound, combinations, methods and uses) may have the advantage that,in the treatment of the conditions described herein, they may be moreconvenient for the physician and/or patient than, be more efficaciousthan, be less toxic than, be longer acting than, have better selectivityover, have a broader range of activity than, be more potent than,produce fewer side effects than, have a better pharmacokinetic and/orpharmacodynamic profile than, have more suitable solid state propertiesthan, have better stability than, or may have other usefulpharmacological properties over, similar compounds, combinations,methods (treatments) or uses known in the prior art for use in thetreatment of those conditions or otherwise.

Relative to compounds of the prior art, in at least some embodiments thecompound of formula (I) is expected to have one or more of the followingattributes:

-   -   it exhibits properties that are particularly suited to        topical/local administration (e.g. following topical/local        administration, the generation of high target tissue        concentrations but low plasma or systemic concentrations of the        compound of formula (I) and/or rapid clearance of the compound        of formula (I) from plasma or the systemic circulation);    -   it has a reduced risk of extravascular exposure following        intravenous administration (e.g. due to a low volume of        distribution for the compound of formula (I));    -   it exhibits superior potency with respect to selected kinases        and/or a panel of kinases, such as p38 MAPKα, p38 MAPKγ, Src and        p59-HCK;    -   it exhibits low or no inhibitory activity against Olaharsky        kinases, particularly GSK3α; it exhibits low or no inhibitory        activity against Syk kinase;    -   it exhibits reduced β-catenin induction and/or inhibition of        mitosis in cells;    -   it exhibits no or less time-dependent inhibition of members of        the cytochrome P450 superfamily; and/or    -   it produces less problematic (e.g. less toxic) metabolites, e.g.        following administration to a patient.

EXPERIMENTAL SECTION

Abbreviations used herein are defined below (Table 1). Any abbreviationsnot defined are intended to convey their generally accepted meaning.

TABLE 1 Abbreviations AcOH glacial acetic acid Ac₂O acetic anhydride Aqaqueous b broad BEH ethylene bridged hybrid BINAP1,1'-binaphthyl-2,2'-diamine Boc tert-butoxycarbonyl CSH charged surfacehybrid d doublet Δ chemical shift DCM dichloromethane DIAD diisopropylazodicarboxylate DMF N,N-dimethylformamide DMSO dimethyl sulfoxide (ES⁺)electrospray ionization, positive mode (ES⁻) electrospray ionization,negative mode Et ethyl EtOAc ethyl acetate EtOH ethanol h hour(s) HATU1-[bis(dimethylamino)methylene]-1H-1,2,3- triazolo[4,5-b]pyridinium3-oxid hexafluorophosphate Hunig's base N,N-diisopropylethylamine IPAisopropyl alcohol ^(i)PrOAc isopropyl acetate m multiplet (M+H)⁺protonated molecular ion (M−H)⁻ deprotonated molecular ion Me methylMeCN acetonitrile MeOH methanol MHz megahertz min minute(s) m/zmass-to-charge ratio NMR nuclear magnetic resonance (spectroscopy)Pd₂(dba)₃ tris(dibenzylideneacetone)dipalladium(0) Ph phenyl q quartetRT room temperature HPLC high performance liquid chromatography ssinglet Sat saturated SCX solid supported cation exchange (resin) ttriplet ^(t)Bu tert-butyl THF tetrahydrofuran TFA trifluoroacetic acidUV ultra-violet AKT v-akt murine thymoma viral oncogene homolog 1 ATPadenosine-5'-triphosphate BALF bronchoalveolar lavage fluid BSA bovineserum albumin COPD chronic obstructive pulmonary disease CXCL1 chemokine(C-X-C motif) ligand 1 COX2 cytochrome c oxidase subunit II DSCdifferential scanning calorimetry DSS dextran sodium sulfate DTTdithiothreitol d-U937 cells PMA differentiated U-937 cells DVS dynamicvapour sorption dsRNA double stranded RNA ELISA enzyme-linkedimmunosorbent assay FACS fluorescence-activated cell sorting FBS foetalbovine serum FRET fluorescence resonance energy transfer GM-CSF CSF2:granulocyte-macrophage colony-stimulating factor GSK3α glycogen synthasekinase 3α GSK3β glycogen synthase kinase 3β HBSS Hank's balanced saltsolution HCK hemopoietic cell kinase HRV human rhinovirus IBDinflammatory bowel disease IC50 50% Inhibitory concentration ICAM-1inter-cellular adhesion molecule 1 IFN interferon IL-2 interleukin 2IL-8 interleukin 8 JNK c-Jun N-terminal kinase KC keratinocytechemoattractant LPMC lamina propria mononuclear cell LPSlipopolysaccharide MAPK mitogen-activated protein kinase MAPKAP-K2mitogen-activated protein kinase-activated protein kinase-2 MKK4mitogen-activated protein kinase kinase 4 MKK6 mitogen-activated proteinkinase kinase 6 MOI multiplicity of infection MTT3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide OD opticaldensity PBMC peripheral blood mononuclear cell PBS Dulbecco's phosphatebuffered saline PHA phytohaemagglutinin PI3 phosphoinositide 3 kinasePMA phorbol 12-myristate 13-acetate REC50 relative 50% effectiveconcentration RNA ribonucleic acid RNAi RNA interference RSV respiratorysyncytical virus SDS sodium dodecyl sulphate SMS surface measurementssystems SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog(avian) Syk spleen tyrosine kinase TCID50 50% tissue culture infectiousdose TGA thermogravimetric analysis TLR3 toll-like receptor 3 TNBS2,4,6-trinitrobenzenesulphonic acid TNFα tumor necrosis factor alphaURTI upper respiratory tract infection XPD powder X-ray diffraction XRDX-ray diffraction

CHEMISTRY EXAMPLES General Procedures

All starting materials and solvents were obtained either from commercialsources or prepared according to the literature citation. Unlessotherwise stated all reactions were stirred. Organic solutions wereroutinely dried over anhydrous magnesium sulfate. Hydrogenations wereperformed on a Thales H-cube flow reactor under the conditions stated.

Column chromatography was performed on pre-packed silica (230-400 mesh,40-63 μm) cartridges using the amount indicated. SCX was purchased fromSupelco and treated with 1M hydrochloric acid prior to use. Unlessstated otherwise the reaction mixture to be purified was first dilutedwith MeOH and made acidic with a few drops of AcOH. This solution wasloaded directly onto the SCX and washed with MeOH. The desired materialwas then eluted by washing with 0.7 M NH₃ in MeOH.

Preparative Reverse Phase High Performance Liquid Chromatography

Performed using UV detection at 215 and 254 nm with either a WatersX-Select Prep-C18, 5 μm, 19×50 mm column eluting with a H₂O-MeCNgradient containing 0.1% v/v formic acid over 10 min, or a WatersX-Bridge Prep-C18, 5 μm, 19×50 mm column eluting with a H₂O-MeCNgradient containing 0.1% ammonium bicarbonate over 10 min.

Analytical Methods Reverse Phase High Performance Liquid Chromatography

Method 1: Waters XSelect CSH C18 2.5 μm (4.6×30 mm) at 40° C.; flow rate2.5-4.5 mL min⁻¹ eluted with a H₂O-MeCN gradient containing 0.1% v/vformic acid over 4 min employing UV detection at 254 nm. Gradientinformation: 0-3.00 min, ramped from 95% H₂O-5% MeCN to 5% H₂O-95% MeCN;3.00-3.01 min, held at 5% H₂O-95% MeCN, flow rate increased to 4.5 mLmin⁻¹; 3.01-3.50 min, held at 5% H₂O-95% MeCN; 3.50-3.60 min, returnedto 95% H₂O-5% MeCN, flow rate reduced to 3.50 mL min⁻¹; 3.60-3.90 min,held at 95% H₂O-5% MeCN; 3.90-4.00 min, held at 95% H₂O-5% MeCN, flowrate reduced to 2.5 mL min⁻¹.

Method 2: Waters XBridge BEH C18, 2.5 μm (4.6×30 mm) at 40° C.; flowrate 2.5-4.5 mL min⁻¹ eluted with a H₂O-MeCN gradient containing 10 mMammonium bicarbonate over 4 min employing UV detection at 254 nm.Gradient information: 0-3.00 min, ramped from 95% H₂O-5% MeCN to 5%H₂O-95% MeCN; 3.00-3.01 min, held at 5% H₂O-95% MeCN, flow rateincreased to 4.5 mL min⁻¹; 3.01-3.50 min, held at 5% H₂O-95% MeCN;3.50-3.60 min, returned to 95% H₂O-5% MeCN, flow rate reduced to 3.50 mLmin⁻¹; 3.60-3.90 min, held at 95% H₂O-5% MeCN; 3.90-4.00 min, held at95% H₂O-5% MeCN, flow rate reduced to 2.5 mL min⁻¹.

¹H NMR Spectroscopy

¹H NMR spectra were acquired on a Bruker Avance III spectrometer at 400MHz using residual undeuterated solvent as reference and unlessspecified otherwise were run in DMSO-d₆.

EXAMPLES Example 1A1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea

Intermediate A: 3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-amine

To a stirred solution of p-tolylhydrazine hydrochloride (100 g, 630mmol) in EtOH (1251 mL) was added 4,4-dimethyl-3-oxopentanenitrile (88g, 699 mmol) and HCl (62.5 mL, 750 mmol). The resulting mixture wasstirred at reflux overnight. The reaction mixture was cooled to roomtemperature and concentrated in vacuo to c.a. ⅓ of the original volume.The reaction mixture was then cooled in an ice-bath and taken to c.a. pH8-9 with 6M aq NaOH. The reaction mixture was extracted with diethylether (500 mL) and the organic phase washed with water (2×300 mL) beforebeing dried over magnesium sulphate and concentrated in vacuo to affordan orange solid. The solid was suspended in iso-hexane and stirred atreflux for 2.5 h before being cooled and filtered whilst still hot toyield the subtitle product 3-tert-butyl-1-p-tolyl-1H-pyrazol-5-amine asa pale brown solid (76.5 g, 52%); R^(t) 1.31 min (Method 1); m/z 230(M+H)⁺ (ES⁺); ¹H NMR δ: 1.20 (9H, s), 2.32 (3H, s), 5.10 (2H, br s),5.35 (1H, s), 7.24 (2H, d), 7.42 (2H, m).

Intermediate B: Phenyl(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)carbamate

A solution of 3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-amine(Intermediate A) (20 g, 87.0 mmol) in isopropyl acetate (240 mL) wasadded to a stirred solution of sodium carbonate (11.3 g, 106 mmol) inwater (80 mL). After 10 min phenyl chloroformate (12.1 mL, 96 mmol) wasadded and the resulting mixture was stirred at ambient temperatureovernight. The reaction mixture was diluted with water (160 mL), thelayers were separated and the organics were washed with water (2×80 mL),brine (80 mL), dried (MgSO₄) and concentrated in vacuo. The resultingyellow solid was suspended in 10% ether/iso-hexane (320 mL) and stirreduntil a uniform suspension was obtained. The solid was collected byfiltration and washed with iso-hexane to yield the subtitle compoundphenyl (3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)carbamate as a whitepowder (27.3 g, 88%); R^(t) 2.65 min (Method 1); m/z 350 (M+H)⁺ (ES⁺);¹H NMR δ:1.29 (9H, s), 2.37 (3H, s), 6.35 (1H, s), 7.10-7.23 (3H,overlapping m), 7.33-7.46 (6H, overlapping m), 9.99 (1H, s).

Intermediate C: tert-Butyl(4-((2-chloropyridin-4-yl)methoxy)naphthalen-1-yl)carbamate

To a mixture of 2-chloro-4-(chloromethyl)pyridine (30 g, 185 mmol) andtert-butyl (4-hydroxynaphthalen-1-yl)carbamate (40.0 g, 154 mmol) inacetonitrile (200 mL) was added caesium carbonate (75 g, 231 mmol) andthe resulting mixture was heated to 55° C. After 16 h the reactionmixture was diluted with 30% MeOH in DCM (600 mL) and water (400 mL).The layers were separated and the aqueous layer was extracted with afurther amount of 30% MeOH in DCM (2×600 mL) and the organics wereconcentrated in vacuo to afford the crude product. The crude product wastriturated with MeOH (200 mL), sonicated for c.a. 5 min and slurried for1 day. The resulting solid was collected by filtration and washed withMeOH (2×10 mL) to yield the subtitle compound tert-butyl(4-((2-chloropyridin-4-yl)methoxy)naphthalen-1-yl)carbamate as a yellowsolid (43 g, 70%); R^(t) 2.60 min (Method 1); m/z 383 (M−H)⁻ (ES⁻); ¹HNMR δ:1.47 (9H, s), 5.41 (2H, s), 6.98 (1H, d), 7.36 (1H, d), 7.55-7.61(3H, overlapping m), 7.65 (1H, m), 7.94 (1H, m), 8.29 (1H, m), 8.45 (1H,m), 9.00 (1H, bs).

Intermediate D (protected): tert-Butyl(44(24(6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)carbamate

A mixture of tert-butyl(4-((2-chloropyridin-4-yl)methoxy)naphthalen-1-yl)carbamate(Intermediate C) (1050 mg, 2.73 mmol), 6-ethylpyrazin-2-amine (437 mg,3.55 mmol), and cesium carbonate (1333 mg, 4.09 mmol) in 1,4-dioxane (15mL) was degassed with nitrogen for 5 min. A solution of Pd₂(dba)₃ (125mg, 0.136 mmol) and BINAP (170 mg, 0.273 mmol) in 1,4-dioxane (5 mL) wasadded, and the reaction mixture stirred at 90° C. for 6 h. The reactionmixture was allowed to cool and was stirred at room temperature for 16h, then diluted with 10% MeOH/DCM (25 mL) and filtered through a plug ofCelite, washing with additional 10% MeOH/DCM (15 mL). The solvent wasremoved in vacuo and the crude product was combined with MeOH (15 mL)and slurried for 3 h. The resulting orange solid was isolated byfiltration, then combined with MeOH/EtOH (5 mL) solution and stirred for72 h. Again the resulting orange solid was isolated by filtration, thenacetone (20 mL) was added and the mixture was slurried for 2 h. Theresidual solid was filtered off, and the filtrate was evaporated to givethe subtitle compound tert-butyl(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)carbamate(360 mg, 27%); R^(t) 2.6 min (Method 2); m/z 472 (M+H)⁺ (ES⁺); ¹H NMR δ:1.18 (3H, t), 1.47 (9H, s), 2.63 (2H, q), 5.36 (2H, s), 6.99 (1H, d),7.06 (1H, d), 7.36 (1H, d), 7.53-7.63 (2H, m), 7.90-8.06 (3H,overlapping m), 8.29 (1H, d), 8.36 (1H, m), 8.91 (1H, s), 8.96 (1H, s),10.06 (1H, s).

Intermediate D:N-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-6-ethylpyrazin-2-amine

TFA (1.485 mL, 19.09 mmol) was added to a solution of tert-butyl(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)carbamate(Intermediate D (protected)) (360 mg, 0.763 mmol) in DCM (15 mL), andthe reaction mixture stirred at room temperature for 4 h, thenconcentrated in vacuo. The residue was combined with sat. sodiumhydrogencarbonate solution and stirred at room temperature for 16 h. Thesolid was filtered, washing with acetonitrile, and dried under vacuum togive the subtitle compoundN-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-6-ethylpyrazin-2-amineas a beige solid (200 mg, 69%); R^(t) 2.14 min (Method 2); m/z 372(M+H)⁺ (ES⁺); ¹H NMR δ: 1.20 (3H, t), 2.64 (2H, q), 5.18-5.24 (4H,overlapping m), 6.59 (1H, d), 6.82 (1H, d), 7.03 (1H, d), 7.41-7.51 (2H,overlapping m), 7.98-8.01 (2H, m), 8.04 (1H, m), 8.22-8.29 (2H,overlapping m), 8.91 (1H, s), 10.04 (1H, s).

1-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea

Triethylamine (0.013 mL, 0.093 mmol) was added to a solution of phenyl(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)carbamate (Intermediate B)(0.042 g, 0.121 mmol) andN-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-6-ethylpyrazin-2-amine(Intermediate D) (0.093 g, 0.250 mmol) in THF (1.5 mL) at 40° C. Thereaction mixture was stirred at 40° C. for 40 min then cooled to RT andstirred for 3 days, and then concentrated in vacuo. The crude productwas purified by silica gel chromatography (12 g column, 0 to 5% MeOH inDCM) to give an off white-brown solid. The product was re-purified bypreparative HPLC (Gilson, Acidic (0.1% Formic acid), Acidic, WatersX-Select Prep-C18, 5 μm, 19×50 mm column, 45-75% MeCN in Water) toafford the title compound1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureaas an off white solid (0.029 g, 49%); R^(t) 2.26 min (Method 1); m/z 627(M+H)⁺ (ES⁺), 625 (M−H)⁻ (ES⁻); ¹H NMR δ: 1.18 (3H, t), 1.28 (9H, s),2.40 (3H, s), 2.63 (2H, q), 5.36 (2H, s), 6.36 (1H, s), 7.02 (1H, d),7.07 (1H, dd), 7.37 (2H, m), 7.45 (2H, m), 7.56-7.67 (3H, overlappingm), 7.94 (1H, m), 7.99 (1H, s), 8.02 (1H, s), 8.30 (1H, d), 8.39 (1H,m), 8.60 (1H, s), 8.81 (1H, s), 8.92 (1H, s), 10.08 (1H, s).

Example 1B1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(different batch)

1-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(10.0 g) was stirred in acetonitrile (770 mL) at 22° C. Theheterogeneous mixture was warmed to reflux temperature at a rate of 3°C./min and reflux was maintained for 2.5 h. The mixture was seeded withcrystalline1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(100 mg). The mixture was linearly cooled to 20° C. over 18 h then againheated to reflux temperature and refluxed for 2 h then linearly cooledto 22° C. over 18 h. The solid product was filtered, washed withacetonitrile (77 mL) and dried for 18 h at 45° C. in vacuo to give1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea (8.73 g).

Example 2A1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 2) Intermediate C: tert-Butyl(4-((2-chloropyridin-4-yl)methoxy)naphthalen-1-yl)carbamate

Acetonitrile (420 mL) was added to 2-chloro-4-(chloromethyl)pyridine(1.05 eq, 59.5 g), and the mixture stirred at 20° C. tert-Butyl(4-hydroxynaphthalen-1-yl)carbamate (90.8 g) was added to the mixturethen potassium carbonate (72.6 g) was added. The heterogeneous mixturewas warmed to 55° C. at a rate of 1.0 K/min.

The mixture was stirred for 16 h at 55° C. then the reaction mixture wascooled to 22° C. Water (1260 mL) was added over 30 min and the mixturewas stirred for 30 min at 22° C. The precipitate was filtered and washedtwice with 200 mL water. The product was dried in vacuo at 50° C. for 20h to give tert-butyl(4-((2-chloropyridin-4-yl)methoxy)naphthalen-1-yl)carbamate (100.0 g,90.6%).

Intermediate D (protected): tert-Butyl(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)carbamate

Dioxane (125 mL) was added to tert-butyl(4-((2-chloropyridin-4-yl)methoxy)naphthalen-1-yl)carbamate(Intermediate C) (9.6 g) and the mixture stirred at 20° C. Cesiumcarbonate (2 eq, 16.3 g) and 2-amino-6-ethylpyrazine (1.5 eq, 4.8 g)were added to the stirred mixture at ° C. Argon was purged through thereaction mixture. Tris(dibenzylideneacetone)dipalladium(0) (0.05 eq,1.14 g) and racemic BINAP (0.10 eq, 1.56 g) were added to the reactionmixture. The mixture was stirred for an additional 15 min at 20° C. Themixture was heated to 90° C. at a rate of 1.5 K/min then stirred for 12h at 90° C. The mixture was cooled to 20° C. and stirring continued foran additional 6 h. The heterogeneous mixture was filtered over Celite,and the filter washed with dioxane (twice 5 mL). The filtrate wasconcentrated in vacuo at 20 mbar and 50° C. The residue was dissolved inethanol (150 mL). Spontaneous crystallization occurred. Theheterogeneous mixture was stirred for 3 h at 22° C. The precipitate wasfiltered and washed with ethanol (10 mL). The product was dried in vacuoat 50° C. for 20 h to give tert-butyl(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)carbamate(9.05 g, 76.8%).

Intermediate D:N-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-6-ethylpyrazin-2-amine

Acetonitrile (200 mL) was added to tert-butyl(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)carbamate(Intermediate D (protected)) (10.5 g) and the heterogeneous mixture wasstirred at 20° C. Sulfuric acid (4.5 eq, 5.5 mL) was added over 2 h at20° C. The heterogeneous mixture was stirred for an additional 2 h at20° C. Aqueous ammonia (10 eq, 17 mL) was added to the reaction mixtureover 15 min and the temperature was kept at 20° C. by cooling. Water(33.4 mL) was added to the heterogeneous mixture over 5 min at 20° C.After stirring for 30 min at 20° C., the mixture was cooled to 5° C. andstirred for an additional 2 h at 5° C. The precipitate was filtered andwashed with water (33.4 mL) and 2-propanol (18 mL). The product wasdried at 50° C. in vacuo for 24 h to giveN-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-6-ethylpyrazin-2-amine(6.2 g, 75%).

1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea

2-methyltetrahydrofuran (1809 mL) was added toN-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-6-ethylpyrazin-2-amine(Intermediate D) (41.3 g) and the mixture was stirred at 20° C. Phenyl(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)carbamate (1.2 eq, 51.3 g)was added to the mixture. Triethylamine (0.25 eq, 3.9 mL) was added andthe mixture stirred for an additional 10 min at 20° C. The heterogeneousreaction mixture was warmed to 48° C. over 30 min and kept at 48° C. for3.5 h. After 10 min at 48° C., the mixture became homogeneous, and wasseeded with crystalline1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(60 mg). The reaction mixture was allowed to cool to 20° C. and stirredfor an additional 16 h. The formed precipitate was filtered and washedwith 2-methyltetrahydrofuran (twice 139 mL). The product was dried for18 h at 45° C. in vacuo to give1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(54.1 g, 77.5%).

1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 2)

2-Butanone (4442 mL) was added to1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(111.04 g) and stirred at 20° C. The heterogeneous mixture was warmed to65° C. and became a homogeneous solution. SilicaMetS Thiol (metalscavenger) (5.55 g) was added and the mixture stirred for 30 min at 65°C. Norit A Supra (activated charcoal) (5.55 g) added and the mixturestirred for an additional 20 min at 65° C. The mixture was filtered warmover Celite. The filter was washed with warm 2-butanone (1555 mL) (60°C.). 2-Butanone (2887 mL) was added to the filtrate and brought to 60°C. while stirring.

Maleic acid (1.0 eq, 20.56 g) was dissolved in 2-butanone (555 mL). Themaleic acid solution was added to the1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureasolution over 80 min at 65° C. After 10% of the maleic acid solution wasadded, the mixture was seeded with crystalline1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 2). The mixture was kept stirring for 1 h at 60° C., thencooled non-linearly with an exponent of 2.3 over 6 h to 5° C. Theprecipitate was filtered and washed twice with 2-butanone (278 mL). Theproduct was dried at 45° C. in vacuo for 20 h to give1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 2) (113.8 g, 86.5%).

Example 2B1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 2) (different batch)

2-Butanone (750 mL) was added to1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea(7.50 g) and the mixture was stirred. The mixture was warmed to 60° C.over 20 min. A solution of maleic acid (1.39 g) in 2-butanone (12 mL)was added to the mixture over 5 min. Spontaneous crystallisationoccurred after approximately half of the maleic acid solution was added.The mixture was stirred for 30 min at 60° C. then cooled to 5° C. over 6h with an exponential ramp (exponent=2.3) then stirred for 30 min at 5°C. then heated to 65° C. over 30 min then stirred for 30 min at 65° C.then cooled to 5° C. over 6 h with an exponential ramp (exponent=2.3)then stirred for 30 min at 5° C. then heated to 65° C. over 30 min thenstirred for 30 min at 65° C. then cooled to 5° C. over 6 h with anexponential ramp (exponent=2.3). The product was filtered and washedtwice with 2-butanone (50 mL), subsequently dried at 45° C. in vacuo togive1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 2) (7.0 g).

Example 2C1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 1)

1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (15 mg) was dissolved in THF (100 vol.) at 50° C. andtemperature cycled between 50° C. and room temperature over 24 h (4 h ateach temperature). The solution was then kept in the fridge for 24 hafter which the solid material (Form 1) was isolated.

Example 2D1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate (Form 1) (different batch)

1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureawas dissolved in THF (40 vol.) at 50° C. and 1 eq of maleic acid wasadded. The sample was left to mature between RT and 50° C. (4 h at eachtemperature) for 2 days. Solid material (Form 1) was isolated.

Example 3 Micronized Batches Example 3A1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureain micronized form

Micronized1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureawas prepared by micronising material from Example 1B in a HosokawaAlpine Spiral Jet Mill 50 AS (5 cm) micronization device (pressure 1.0bar) (manual feed). The particle size volume parameters determined bylaser diffraction using a Malvern Mastersizer 2000S (dispersion inwater/Tween80, 0.1% w/v) are given in the table below:

Dv10 (micron) Dv50 (micron) Dv90 (micron) 0.15 1.54 10.76

Example 3B1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureamaleate Form 2 in micronized form

Micronized1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea maleate (Form 2) was preparedby micronising material from Example 2B in a Hosokawa Alpine Spiral JetMill 50 AS (5 cm) micronization device (pressure 1.0 bar) (manual feed).The particle size volume parameters determined by laser diffractionusing a Malvern Mastersizer 2000S (dispersion in water/Tween80, 0.1%w/v) for the input and output material are given in the table below:

Dv10 (micron) Dv50 (micron) Dv90 (micron) Input material 3 9 128(Example 2B) Output material 1.21 2.18 4.00 (Example 3B)

Example 4 Lactose containing compositions containing1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)ureaas free base and maleate (Form 2), suitable for inhalation

Compositions were prepared by blending ingredients as follows:

Active ingredient (Example 3B) (maleate (Form 2), Lactose MagnesiumExample micronised) monohydrate* stearate** 4a 75 mg 75 mg — 4b 75 mg —75 mg 4c 75 mg 35 mg 35 mg Active ingredient (Example 3A) (free baseform, Lactose Magnesium Example micronised)** monohydrate* stearate** 4d 10 μg 25 mg — 4e  10 μg 25 mg 1% 4f 100 μg 25 mg — Active ingredient(Example 3B) (maleate (Form 2), Lactose Magnesium Example micronised)monohydrate* stearate** 4g  10 μg 25 mg — 4h  10 μg 25 mg 1% 4i 100 μg25 mg — *Lactohale LH200 **Source: Peter Greven (Grade: Ligamed MF-2V;vegetable grade)

Example 5 Characterisation and Stability Testing PhysicalCharacterisation of the Active Ingredient

Infrared Spectrometry (IR)—Micro Attenuated Total Reflectance (microATR)

The samples were analyzed using a suitable microATR accessory.

number of scans: 32resolution: 1 cm⁻¹wavelength range: 4000 to 400 cm⁻¹apparatus: Thermo Nexus 670 FTIR spectrometerdetector: DTGS with KBr windowsbeamsplitter: Ge on KBrmicro ATR accessory: Harrick Split Pea with Si crystal

The IR spectrum of a sample of Example 2A material, shown in FIG. 1,reflects the vibrational modes of the molecular structure of Example 1as its maleate salt.

Powder XRD

Powder X-ray diffraction (XPD) analysis on the Form 2 material wascarried out on a PANanalytical (Philips) X'PertPRO MPD diffractometer.The instrument is equipped with a Cu LFF X-ray tube.

The compound was spread on a zero background sample holder.

Instrument Parameters:

generator voltage: 45 kVgenerator amperage:geometry: Bragg-Brentanostage: spinner stage

Measurement Conditions:

scan mode: continuousscan range: 3 to 50° 2θstep size: 0.02°/stepcounting time: 30 sec/stepspinner revolution time: 1 secradiation type: CuKα

Incident beam path: Diffracted beam path: program. divergence slit: 15mm long anti scatter shield: + Soller slit: 0.04 rad Soller slit: 0.04rad beam mask: 15 mm Ni filter: + anti scatter slit: 1° detector:X'Celerator beam knife: +

Powder X-ray diffraction (XPD) analysis on the Form 1 material wascarried out on a Bruker AXS C2 GADDS diffractometer. The compound waslightly pressed on a glass slide.

Instrument Parameters:

-   -   generator voltage: 40 kV        generator amperage: 40 mA        geometry: reflection (=Bragg-Brentano)        stage: automated XYZ stage

Measurement Conditions:

scan mode: continuousscan range: 3 to 30° 2θstep size: 0.05°/stepcounting time: 120 secradiation type: CuKαdetector: HiStar 2-dimensionalSingle Göbel multilayer mirror coupled with a pinhole collimator of 0.3mm

The powder XRD pattern of a sample of Example 2A material, shown in FIG.2, shows diffraction peaks without the presence of a halo, indicatingthat the compound is present as a crystalline product. This XRD patternis characteristic of crystalline polymorph Form 2.

The powder XRD pattern of a sample of Example 2D material, shown in FIG.3, shows diffraction peaks without the presence of a halo, indicatingthat the compound is present as a crystalline product. This XRD patternis characteristic of crystalline polymorph Form 1.

Differential Scanning Calorimetry (DSC)

About 3 mg of the test compound was transferred into a standard aluminumTA-Instrument sample pan. The sample pan was closed with the appropriatecover and the DSC curve recorded on a TA-Instruments Q1000 MTDSCequipped with a RCS cooling unit.

The following parameters were used:

initial temperature: 25° C.heating rate: 10° C./minfinal temperature: 300° C.nitrogen flow: 50 mL/min

The DSC curve of a sample of Example 2A material, shown in FIG. 4,reveals the melting with decomposition of the product at about 198.6° C.(Form 2).

Thermogravimetric Analysis (TGA)

The test compound was transferred into an aluminum sample pan. Thethermogravimetric curve was recorded on a TA Instruments Q500thermogravimeter. The following parameters were used:

initial temperature: room temperatureheating rate: 20° C./minresolution factor: 4final condition: 300° C. or <80[(w/w) %]

A TGA plot of a sample of Example 2A material is shown in FIG. 5. Noweight loss was registered in the temperature region from roomtemperature up to 175° C. The weight loss above 175° C. is due toevaporation and decomposition of the product.

Dynamic Vapour Sorption (DVS)

About 20 mg of test compound was transferred into a SMS dynamic vaporsorption and record the weight change with respect to the atmospherichumidity at 25° C.

The following parameters were used:

drying: 60 min. under dry nitrogenequilibrium: 60 min/Step.RH (%) measurement points:first set: 5,10,20,30,40,50,60,70,80,90,95,90,80,70,60,50,40,30,20,10,5second set: 10,20,30,40,50,60,70,80,90,95,90,80,70,60,50,40,30,20,10,5,0

DVS testing was performed on a sample of Example 2A material (see FIGS.6 and 7). During the initial drying step, a weight loss of 0.3% wasregistered. The product does not appear to be hygroscopic.

The product after DVS, was investigated by XRD and IR and remained inthe same solid state form before the test as after the test (data notshown). No indication for dissociation of the salt was observed.

Scanning Electron Microscopy (SEM)

For SEM experiments, data were collected on a Phenom Pro ScanningElectron Microscope. A small quantity of sample was mounted onto analuminium stub using conducting double-sided adhesive tape. A thin layerof gold was applied using a sputter coater (20 mA, 120 sec).

Samples of Form 1 and Form 2 material of the maleate salt of thecompound of the invention were inspected by SEM. Form 1 product had aneedle like morphology. Form 2 product had a plate like morphology. Theplate like morphology of Form 2 is more suitable for the preparation ofan inhaled product than the needle like morphology of Form 1.

Summary of Results of Physical Characterisation of the Active Ingredient

The tested material was crystalline based on XRD and melts withdecomposition at around 198.6° C. No weight loss was observed betweenroom temperature and 175° C. by TGA. The material appeared not to behygroscopic. There was no evidence of solid state conversion ordissociation of the salt. These properties confirm the suitability ofthe compound of formula (I) maleate salt as a candidate drug.

Physical Characterisation of the Active Ingredient in Micronised Form

A sample of Example 3B material was studied by IR, powder XRD, DSC, TGAand DVS in a similar manner to that described above for Example 2Amaterial. The IR and powder XRD results were substantially the same(data not shown). The tested material was crystalline based on XRD andmelts with decomposition at around 194.6° C. according to DSC. Thematerial appeared not to be hygroscopic (data not shown). There was noevidence of solid state conversion or dissociation of the salt (data notshown). These properties confirm the suitability of the compound offormula (I) maleate salt in micronized form as a candidate drug.

Physical Stability Testing—Stability of Lactose Blends

The compositions of Examples 4a, 4b and 4c were stored for 3, 6 and 13weeks under conditions of 40° C./75% RH, 50° C./80% RH and 50°C./ambient RH. XRD patterns and IR spectra were obtained at time zeroand at the three time points (testing parameters were the same asdescribed for characterisation of active ingredient, above). No relevantdifferences in the XRD patterns or IR spectra were were observed betweentime zero and any of the time points (data not shown). No solid stateform changes or dissociation of the salt was observed.

Chemical Stability Testing—Stability of Active Ingredient and BlendsUPLC Method for Degradation Determination

Samples were extracted with solvent mixture (DMSO/water 80:20) (7 mL) ina 10 mL vial. UPLC chromatography was performed using the followingparameters:

Column: Supelco Ascentis Express C18, 150 mm length×3.0 mm i.d., 2.7 μmparticle size

Column Temperature: 30° C. Autosampler Temperature: 5° C.

Flow Rate: 0.40 mL/min

Mobile Phase:

Solvent A: 10 mM ammonium acetate (0.771 g/L)+0.1% v/v trifluoraceticacid in waterSolvent B: acetonitrile/isopropyl alcohol 70:30 (v/v)

Gradient:

Time in minutes Solvent 0 20 25 30 31 36 % A 90 35 0 0 90 90 % B 10 65100 100 10 10Analysis run time: 36 minData collection time: 30 minInjection volume: 5 μLWavelength: scan between 200 and 400 nmWavelength used for content uniformity calculations: 334.0 nm

The compositions of Examples 4d, 4e, 4f, 4g, 4h and 4i were stored for14 and 30 days under conditions of 50° C./75° RH, 60° C./30% RH, 60°C./50% RH, 70° C./10% RH, 70° C./75% RH and 80° C./50% RH.

Degradation was measured at time zero and the time points of 7, 14 and30 days by UPLC and the results are shown in FIG. 8, plates A to F.

The percentage of total degradation for compositions containing themaleate salt, Form 2 of the active ingredient was always lower than thatfor equivalent compositions containing the free base of the activeingredient indicating that the maleate salt, Form 2 is more stable inthese formulations. The percentage of total degradation for compositionscontaining the maleate salt, Form 2 of the active ingredient at higherconcentration was lower than that for compositions containing themaleate salt, Form 2 of the active ingredient at lower concentration inthese formulations.

In similar studies on Example 1B and Example 2B material (i.e.unmicronised and unblended material) in which samples were stored for upto 30 days under conditions of 50° C./75% RH, 60° C./50% RH, 70° C./10%RH, 70° C./75% RH and 80° C./50% RH, qualitatively similar results wereobtained i.e. the percentage of total degradation for the maleate saltwas always lower than that for the free base (data not shown).

From these results it appears that the maleate salt of the compound ofthe invention is more chemically stable (alone and in combination withlactose) than the free base form.

Example 6 Biological Testing Experimental Methods for Biological TestingEnzyme Inhibition Assays

The enzyme inhibitory activities of the compound disclosed herein weredetermined by FRET using synthetic peptides labelled with both donor andacceptor fluorophores (Z-LYTE, Life Technologies, Paisley, UK).

p38 MAPKα Enzyme Inhibition

The inhibitory activities of the compound of the invention against thep38 MAPKα isoform (MAPK14: Life Technologies), were evaluated indirectlyby determining the level of activation/phosphorylation of the targetpeptide of the p38 MAPKα down-stream molecule, MAPKAP-K2. The enzyme (40ng/mL, 2.5 μL) was incubated with the test compound (2.5 μL of either 40μg/mL, 12 μg/mL, 4 μg/mL, 1.2 μg/mL, 0.4 μg/mL, 0.12 μg/mL, 0.04 μg/mL,0.012 μg/mL, 0.004 μg/mL or 0.0012 μg/mL) for 2 h at RT. The FRETpeptides (8 μM, 2.5 μL) and the p38α inactive target MAPKAP-K2 (LifeTechnologies, 2000 ng/mL), and appropriate ATP solution (2.5 μL, 40 μM)were then added to the enzyme/compound mixture and incubated for 1 h atRT. Development reagent (protease, 5 μL) was added for 1 h prior todetection in a fluorescence microplate reader (EnVision, Perkin Elmer,Waltham, Mass., USA).

p38 MAPKγ Enzyme Inhibition

The inhibitory activities of the compound of the invention againstp38MAPKγ (MAPK12: Life Technologies), were evaluated by determining thelevel of activation/phosphorylation of the target peptide. The enzyme(800 ng/mL, 2.5 μL) was incubated with the test compound (2.5 μL ateither 40 μg/mL, 12 μg/mL, 4 μg/mL, 1.2 μg/mL, 0.4 μg/mL, 0.12 μg/mL,0.04 μg/mL, 0.012 μg/mL, 0.004 μg/mL or 0.0012 μg/mL) for 2 h at RT. TheFRET peptides (8 μM, 2.5 μL), and appropriate ATP solution (2.5 μL, 400μM) were then added to the enzymes/compound mixtures and incubated for 1h at RT. Development reagent (protease, 5 μL) was added for 1 h prior todetection in a fluorescence microplate reader (EnVision, Perkin Elmer).

Hck, c-Src and Syk Enzyme Inhibition

The inhibitory activities of the compound of the invention against Hck,c-Src and Syk enzymes (Life Technologies) were evaluated in a similarfashion to that described hereinabove. The relevant enzyme (1000 ng/mL,1400 ng/mL or 2000 ng/mL respectively, 2.5 μL) was incubated with thetest compound (either 40 μg/mL, 12 μg/mL, 4 μg/mL, 1.2 μg/mL, 0.4 μg/mL,0.12 μg/mL, 0.04 μg/mL, 0.012 μg/mL, 0.004 μg/mL or 0.0012 μg/mL, 2.5 μLeach) for 2 h at RT. The FRET peptides (8 μM, 2.5 μL), and appropriateATP solutions (2.5 μL, 800 μM for c-Src, and 60 μM ATP for HCK and Syk)were then added to the enzyme/compound mixtures and incubated for 1 h atRT. Development reagent (protease, 5 μL) was added for 1 h prior todetection in a fluorescence microplate reader (EnVision, Perkin Elmer).

GSK 3α Enzyme Inhibition

The inhibitory activities of the compound of the invention against theGSK 3α enzyme isoform (Life Technologies) were evaluated in a similarfashion to that described hereinabove. The GSK3α protein (500 ng/mL, 2.5μL) was incubated with the test compound (2.5 μL at either 40 μg/mL, 12μg/mL, 4 μg/mL, 1.2 μg/mL, 0.4 μg/mL, 0.12 μg/mL, 0.04 μg/mL, 0.012μg/mL, 0.004 μg/mL or 0.0012 μg/mL) for 2 h at RT. The FRET peptide (8μM, 2.5 μL), which is a phosphorylation target for GSK3α, and ATP (40μM, 2.5 μL) were then added to the enzyme/compound mixture and theresulting mixture incubated for 1 h at RT. Development reagent(protease, 5 μL) was added for 1 h prior to detection in a fluorescencemicroplate reader (EnVision, Perkin Elmer).

In all cases, the site-specific protease cleaves non-phosphorylatedpeptide only and eliminates the FRET signal. Phosphorylation levels ofeach reaction were calculated using the ratio of coumarin emission(donor) over fluorescein emission (acceptor), for which low ratiosindicate high phosphorylation and high ratios indicate lowphosphorylation levels. The percentage inhibition of each reaction wascalculated relative to non-inhibited control and the 50% inhibitoryconcentration (IC₅₀ value) was then calculated from theconcentration-response curve.

Cellular Assays (Employed in the Examples)

The following cellular assays were employed to assess the compound ofthe present invention and the results are given infra.

LPS-induced TNFα/IL-8 Release in d-U937Cells

U937 cells, a human monocytic cell line, were differentiated intomacrophage-type cells by incubation with PMA (100-200 ng/mL) for 48 to72 hr. Cells were pre-incubated with final concentrations of testcompound for 2 h and were then stimulated with LPS (0.1 μg/mL; from E.coli: O111:B4, Sigma) for 4 h. The supernatant was collected fordetermination of TNFα and IL-8 concentrations by sandwich ELISA(Duo-set, R&D systems). The inhibition of TNFα production was calculatedas a percentage of that achieved by 10 μg/mL of BIRB796 at eachconcentration of test compound by comparison against vehicle control.The relative 50% effective concentration (REC₅₀) was determined from theresultant concentration-response curve. The inhibition of IL-8production was calculated at each concentration of test compound bycomparison with vehicle control. The 50% inhibitory concentration (IC₅₀)was determined from the resultant concentration-response curve.

Poly I:C-Induced ICAM-1 Expression in BEAS2B Cells

Poly I:C was used in these studies as a simple, RNA virus mimic. PolyI:C-Oligofectamine mixture (2% Oligofectamine ±1 μg/mL Poly I:C, 25 μL;Life Technologies and Invivogen Ltd., San Diego, Calif., respectively)was transfected into BEAS2B cells (human bronchial epithelial cells,ATCC). Cells were pre-incubated with final concentrations of testcompounds for 2 h and the level of ICAM-1 expression on the cell surfacewas determined by cell-based ELISA. At a time point 18 h after poly I:Ctransfection, cells were fixed with 4% formaldehyde in PBS (100 μL) andthen endogenous peroxidase was quenched by the addition of washingbuffer (100 μL, 0.05% Tween in PBS: PBS-Tween) containing 0.1% sodiumazide and 1% hydrogen peroxide. Cells were washed with wash-buffer(3×200 μL). After blocking the wells with 5% milk in PBS-Tween (100 μL)for 1 h, the cells were incubated with anti-human ICAM-1 antibody (50μL; Cell Signaling Technology, Danvers, Mass.) in 1% BSA PBS overnightat 4° C.

The cells were washed with PBS-Tween (3×200 μL) and incubated with thesecondary antibody (100 μL; HRP-conjugated anti-rabbit IgG, Dako Ltd.,Glostrup, Denmark). The cells were then incubated with of substrate (50μL) for 2-20 min, followed by the addition of stop solution (50 μL, 1NH₂SO₄). The ICAM-1 signal was detected by reading the absorbance at 450nm against a reference wavelength of 655 nm using a spectrophotometer.The cells were then washed with PBS-Tween (3×200 μL) and total cellnumbers in each well were determined by reading absorbance at 595 nmafter Crystal Violet staining (50 μL of a 2% solution in PBS) andelution by 1% SDS solution (100 μL) in PBS. The measured OD 450-655readings were corrected for cell number by dividing with the OD595reading in each well. The inhibition of ICAM-1 expression was calculatedat each concentration of test compound by comparison with vehiclecontrol. The 50% inhibitory concentration (IC₅₀) was determined from theresultant concentration-response curve.

Cell Mitosis Assay

Peripheral blood mononucleocytes (PBMCs) from healthy subjects wereseparated from whole blood (Quintiles, London, UK) using a densitygradient (Histopaque®-1077, Sigma-Aldrich, Poole, UK). The PBMCs (3million cells per sample) were subsequently treated with 2% PHA(Sigma-Aldrich, Poole, UK) for 48 h, followed by a 20 h exposure tovarying concentrations of test compounds. At 2 h before collection,PBMCs were treated with demecolcine (0.1 μg/mL; Life Technologies,Paisley, UK,) to arrest cells in metaphase. To observe mitotic cells,PBMCs were permeabilised and fixed by adding Intraprep (50 μL; BeckmanCoulter, France), and stained with anti-phospho-histone 3 (0.26 ng/L;#9701; Cell Signalling) and propidium iodide (1 mg/mL; Sigma-Aldrich aspreviously described (Muehlbauer P. A. et al., Mutation Res., 2003, 537,117-130). Fluorescence was observed using an ATTUNE flow cytometer (LifeTechnologies), gating for lymphocytes. The percentage inhibition ofmitosis was calculated for each treatment relative to vehicle (0.5%DMSO) treatment.

The Effect of Test Compounds on Cell Viability: MTT Assay

Differentiated U937 cells were pre-incubated with each test compound(final concentration 10 μg/mL in 200 μL media indicated below) under twoprotocols: the first for 4 h in 5% FCS RPMI1640 media and the second in10% FCS RPMI1640 media for 24 h. The supernatant was replaced with newmedia (200 μL) and MTT stock solution (10 μL, 5 mg/mL) was added to eachwell. After incubation for 1 h the media were removed, DMSO (200 μL) wasadded to each well and the plates were shaken lightly for 1 h prior toreading the absorbance at 550 nm. The percentage loss of cell viabilitywas calculated for each well relative to vehicle (0.5% DMSO) treatment.Consequently an apparent increase in cell viability for drug treatmentrelative to vehicle is tabulated as a negative percentage.

Cytokine Production in LPS-Treated Sputum Macrophages from COPD Patients

Patients with COPD inhaled a nebulised solution of 3% (w/v) hypertonicsaline using an ultrasonic nebuliser (Devilbiss, Carthage, Mo.) withtidal breathing for 5 min. This procedure was repeated a maximum ofthree times until enough sputum was obtained. The sputum samples werehomogenized and mixed vigorously using a vortex mixer in 0.02% v/vdithiothreitol (DTT) solution. The samples were re-suspended in PBS (40mL) followed by centrifugation at 1500 rpm at 4° C. for 10 min to obtainsputum cell pellets. The pellets were washed with PBS (40 mL). Thesputum cells were then re-suspended in 4 mL macrophage serum-free medium(macrophage-SFM, Life technologies, containing 20 U/mL penicillin, 0.02mg/mL streptomycin and 5 μg/mL amphotericin B) and seeded on high bound96-well plate, followed by incubation for 1 h at 37° C. and at 5% CO₂ toallow the macrophages to attach to the bottom of the plate. The cells onthe plate were washed with fresh macrophage-SFM (200 μL/well) to removeneutrophils and other contaminated cells. The adherent cells (mainlysputum macrophages) on the plate were used for further analysis. Sputuminductions were conducted in Quintiles Drug Research Unit at GuysHospital and ethics approval and written informed consent was obtainedby Quintiles.

Where appropriate, 1 μL of a solution containing either the testcompound or reference article at the stated concentrations (either 0.1μg/mL, 0.01 μg/mL, or 0.001 μg/mL) or alternatively 1 μL of DMSO as thevehicle control was added to each well (200 μL in media) and the cellswere incubated for 2 h. The cells were stimulated with LPS solution (50μL, final concentration: 1 μg/mL) and incubated for 18 h at 37° C. and5% CO₂. The supernatant was then collected and kept at −80° C. Suitableluminex kits were used to measure the selected analytes. After thawingthe supernatant, the magnetic antibody beads were multiplexed andincubated in a 96-well plate with standard, background solution or theappropriate volume of sample overnight with shaking at 4° C. Afterwashing twice with 200 μL of wash buffer provided by the kit per wellusing a magnetic plate washer, the beads were incubated for 1 h at RTwith the biotin conjugated antibody solution provided by the kit withshaking. Streptavidin solution was added for 30 min with shaking at RT.After washing with 200 μL wash buffer per well, the beads wereresuspended in sheath fluid (150 μL) and analyzed immediately. The levelof each analyte in the supernatant was calculated using Xcel Fitsoftware with a 4 or 5-parameter equation using each standard curve. Theinhibitions of each cytokine production were calculated at eachconcentration by comparison with vehicle control.

Rhinovirus-Induced IL-8 Release

Human rhinovirus RV16 is obtained from the American Type CultureCollection (Manassas, Va.). Viral stocks are generated by infecting MRC5cells with HRV until 80% of the cells were cytopathic.

BEAS2B cells are infected with HRV at an MOI of 1.2 and incubated for 1h at 33° C. with gentle shaking for to promote absorption. The cells arethen washed with PBS, fresh media added and the cells are incubated fora further 72 h. The supernatant is collected for assay of IL-8concentrations using a Duoset ELISA development kit (R&D systems,Minneapolis, Minn.). Compounds are added 2 h before HRV infection and 1h after infection when non-infected HRV is washed out.

Cellular Assays (not Employed in the Examples)

The following cellular assays could be employed to assess the compoundof the present invention:

Rhinovirus-Induced IL-8 Release (Variation on the Above Method) andICAM-1 Expression

Human rhinovirus RV16 is obtained from the American Type CultureCollection (Manassas, Va.). Viral stocks are generated by infecting Helacells with HRV until 80% of the cells were cytopathic.

BEAS2B cells are infected with HRV at an MOI of 5 and incubated for 1 to2 h at 33° C. with gentle shaking to promote absorption. The cells arethen washed with PBS, fresh media added and the cells are incubated fora further 72 h. The supernatant is collected for assay of IL-8concentrations using a Duoset ELISA development kit (R&D systems,Minneapolis, Minn.).

The level of cell surface ICAM-1 expression is determined by cell-basedELISA. At 72 h after infection, cells were fixed with 4% formaldehyde inPBS. After quenching endogenous peroxidase by adding 0.1% sodium azideand 1% hydrogen peroxide, wells are washed with wash-buffer (0.05% Tweenin PBS: PBS-Tween). After blocking well with 5% milk in PBS-Tween for 1h, the cells are incubated with anti-human ICAM-1 antibody in 5% BSAPBS-Tween (1:500) overnight. Wells are washed with PBS-Tween andincubated with the secondary antibody (HRP-conjugated anti-rabbit IgG,Dako Ltd.). The ICAM-1 signal is detected by adding substrate andreading at 450 nm with a reference wavelength of 655 nm using aspectrophotometer. The wells are then washed with PBS-Tween and totalcell numbers in each well were determined by reading absorbance at 595nm after Crystal Violet staining and elution by 1% SDS solution. Themeasured 0D₄₅₀₋₆₅₅ readings are corrected for cell number by dividingwith the 0D₅₉₅ reading in each well. Compounds are added 2 h before HRVinfection and 1 to 2 h after infection when non-infected HRV is washedout.

LPS-Induced TNFα/IL-8 Release in PBMC Cells

Peripheral blood mononuclear cells (PBMCs) from healthy subjects areseparated from whole blood using a density gradient (Lymphoprep,Axis-Shield Healthcare). The PBMCs are seeded in 96 well plates andtreated with compounds at the desired concentration for 2 h beforeaddition of 1 ng/mL LPS (Escherichia coli 0111:B4 from Sigma Aldrich)for 24 h under normal tissue culture conditions (37° C., 5% CO₂). Thesupernatant is harvested for determination of and TNFα concentrations bysandwich ELISA (Duo-set, R&D systems) and read on the fluorescencemicroplate reader (Varioskan® Flash, ThermoFisher Scientific).

The concentration at 50% inhibition (IC₅₀) of IL-8 and TNFα productionis calculated from the dose response curve.

IL-2 and IFN Gamma Release in CD3/CD28 Stimulated PBMC Cells

PBMCs from healthy subjects are separated from whole blood using adensity gradient (Lymphoprep, Axis-Shield Healthcare). Cells are addedto a 96 well plate pre-coated with a mixture of CD3/CD28 monoclonalantibodies (0.3 μg/mL eBioscience and 3 μg/mL BD Pharmingenrespectively). Compound at the desired concentration is then added tothe wells and the plate left for 3 days under normal tissue cultureconditions. Supernatants are harvested and IL-2 and IFN gamma releasedetermined by Sandwich ELISA (Duo-set, R&D System). The IC₅₀ isdetermined from the dose response curve.

IL-1β-Induced IL-8 Release in HT29 Cells

HT29 cells, a human colon adenocarcinoma cell line, are plated in a 96well plate (24 h) and pre-treated with compounds at the desiredconcentration for 2 h before addition of 5 ng/mL of IL-1β (Abcam) for 24h. Supernatants are harvested for IL-8 quantification by Sandwich ELISA(Duo-set, R&D System). The IC₅₀ is determined from the dose responsecurve.

T Cell Proliferation

PBMCs from healthy subjects are separated from whole blood using adensity gradient (Lymphoprep, Axis-Shield Healthcare). The lymphocytefraction is first enriched for CD4+ T cells by negative magnetic cellsorting as per the manufacturer's instructions (Miltenyi Biotec130-091-155). Naïve CD4+ T cells are then separated using positivemagnetic selection of CD45RA+ cells using microbeads as per themanufacturer's instructions (130-045-901). Cells are plated at 2×10⁵cells per well in 100 μL RPMI/10% FBS on 96 well flat bottomed plate(Corning Costar). 25 μL of test compound are diluted to the appropriateconcentration (8× final conc.) in normal medium and added to duplicatewells on the plate to achieve a dose response range of 0.03 ng/mL-250ng/mL. DMSO is added as a negative control. Plates are allowed topre-incubate for 2 h before stimulation with 1 μg/mL anti-CD3 (OKT3;eBioscience). After 72 h, the medium in each well is replaced with 150μL of fresh medium containing 10 μM BrdU (Roche). After 16 h, thesupernatant is removed, the plate is dried and the cells fixed by adding100 μL of fix/denature solution to each well for 20 min as per themanufacturer's instructions (Roche). Plates are washed once with PBSbefore addition of the anti-BrdU detection antibody and incubated for 90min at room temperature. Plates are then washed gently 3× with the washbuffer supplied and developed by addition of 100 μL of substratesolution. The reaction is stopped by addition of 50 μL of 1 M H₂SO₄, andread for absorbance at 450 nm on a plate reader (Varioskan® Flash,ThermoFisher Scientific). The IC₅₀ is determined from the dose responsecurve.

Human Biopsy Assay

Intestinal mucosa biopsies are obtained from the inflamed regions of thecolon of IBD patients. The biopsy material is cut into small pieces (2-3mm) and placed on steel grids in an organ culture chamber at 37° C. in a5% CO₂/95% O₂ atmosphere in serum-free media. DMSO control or testcompounds at the desired concentration are added to the tissue andincubated for 24 h in the organ culture chamber. The supernatant isharvested for determination of IL-6, IL-8, IL-1β and TNFα levels by R&DELISA. Percentage inhibition of cytokine release by the test compoundsis calculated relative to the cytokine release determined for the DMSOcontrol (100%).

IL-2 and IFNγ Release in CD3/CD28 Stimulated LPMC Cells from IBDPatients

Lamina propria mononuclear cells (LPMCs) are isolated and purified frominflamed IBD mucosa of surgical specimens or from normal mucosa ofsurgical specimens as follows: The mucosa is removed from the deeperlayers of the surgical specimens with a scalpel and cut in fragments 3-4mm size. The epithelium is removed by washing the tissue fragments threetimes with 1 mM EDTA (Sigma-Aldrich, Poole, UK) in HBSS (Sigma-Aldrich)with agitation using a magnetic stirrer, discarding the supernatantafter each wash. The sample is subsequently treated with type 1Acollagenase (1 mg/mL; Sigma-Aldrich) for 1 h with stirring at 37° C. Theresulting cell suspension is then filtered using a 100 μm cell strainer,washed twice, resuspended in RPMI-1640 medium (Sigma-Aldrich) containing10% fetal calf serum, 100 U/mL penicillin and 100 μg/mL streptomycin,and used for cell culture.

Freshly isolated LPMCs (2×10⁵ cells/well) are stimulated with 1 μg/mLα-CD3/α-CD28 for 48 h in the presence of either DMSO control orappropriate concentrations of compound. After 48 h, the supernatant isremoved and assayed for the presence of TNFα and IFNγ by R&D ELISA.Percentage inhibition of cytokine release by the test compounds iscalculated relative to the cytokine release determined for the DMSOcontrol (100%).

Inhibition of Cytokine Release from Myofibroblasts Isolated from IBDPatients

Myofibroblasts from inflamed IBD mucosa are isolated as follows:

The mucosa is dissected and discarded and 1 mm-sized mucosal samples arecultured at 37° C. in a humidified CO₂ incubator in Dulbecco's modifiedEagle's medium (DMEM, Sigma-Aldrich) supplemented with 20% FBS, 1%non-essential amino acids (Invitrogen, Paisley, UK), 100 U/mLpenicillin, 100 μg/mL streptomycin, 50 μg/mL gentamycin, and 1 μg/mLamphotericin (Sigma-Aldrich). Established colonies of myofibroblasts areseeded into 25-cm² culture flasks and cultured in DMEM supplemented with20% FBS and antibiotics to at least passage 4 to provide a sufficientquantity for use in stimulation experiments.

Subconfluent monolayers of myofibroblasts are then seeded in 12-wellplates at 3×10⁵ cells per well are starved in serum-free medium for 24 hat 37° C., 5% CO₂ before being cultured for 24 h in the presence ofeither DMSO control or appropriate concentrations of compound. After 24h the supernatant is removed and assayed for the presence of IL-8 andIL-6 by R&D ELISA. Percentage inhibition of cytokine release by the testcompounds is calculated relative to the cytokine release determined forthe DMSO control (100%).

Human Neutrophil Degranulation

Neutrophils are isolated from human peripheral blood as follows:

Blood is collected by venepuncture and anti-coagulated by addition of1:1 EDTA: sterile phosphate buffered saline (PBS, no Ca+/Mg+). Dextran(3% w/v) is added (1 part dextran solution to 4 parts blood) and theblood allowed to stand for approximately 20 min at RT. The supernatantis carefully layered on a density gradient (Lymphoprep, Axis-ShieldHealthcare) and centrifuged (15 min, 2000 rpm, no brake). Thesupernatant is aspirated off and the cell pellet is re-suspended insterile saline (0.2%) for no longer than 60 seconds (to lysecontaminating red blood cells). 10 times volume of PBS is then added andthe cells centrifuged (5 min, 1200 rpm). Cells are re-suspended in HBSS+(Hank's balanced salt solution (without phenol red) containingcytochalasin B (5 μg/mL) and 1 mM CaCl₂) to achieve 5×10⁶ cells/mL.

5×10⁴ cells are added to each well of a V-bottom 96 well plate andincubated (30 min, 37° C.) with the appropriate concentration of testcompound (0.3-1000 ng/mL) or vehicle (DMSO, 0.5% final conc).Degranulation is stimulated by addition of fMLP (final conc 1 μM) whichafter a further incubation (30 min, 37° C.) the cells are removed bycentrifugation (5 min, 1500 rpm) and the supernatants transferred to aflat bottom 96 well plate. An equal volume of tetramethylbenzidine (TMB)is added and after 10 min the reaction terminated by addition of anequal volume of sulphuric acid (0.5 M) and absorbance read at 450 nm(background at 655 nm subtracted). The 50% inhibitory concentration(IC₅₀) is determined from the resultant concentration-response curve.

Cell Cytotoxicity Assay

5×10⁴ TK6 cells (lymphoblastic T cell line) are added to the appropriatenumber of wells of a 96 well plate in 195 μL of media (RPMI supplementedwith 10% foetal bovine serum). 5 μL of DMSO control (final concentration0.5% v/v) or test compound (final concentration either 5 or 1 μg/mL) isadded to the wells and incubated at 37° C., 5% CO₂. After 24 h, theplate is centrifuged at 1300 rpm for 3 min and the supernatantdiscarded. Cells are then resuspended in 7.5 μg/mL propidium iodide (PI)in PBS. After 15 min, cells are analysed by flow cytometry (BD accuri).The % viability is calculated as the % of cells that are PI negative inthe test wells normalised to the DMSO control.

In Vivo Screening: Pharmacodynamics and Anti-Inflammatory Activity(Employed in the Examples)

The following in vivo screens were employed to assess the compound ofthe present invention and the results are given infra.

LPS-Induced Neutrophil Accumulation in Mice

Non-fasted Balb/c mice were dosed by the intra tracheal route witheither vehicle, or the test substance at the indicated times (within therange 2-8 h) before stimulation of the inflammatory response byapplication of an LPS challenge. At T=0, mice were placed into anexposure chamber and exposed to LPS (7.0 mL, 0.5 mg/mL solution in PBSfor 30 min). After a further 8 h the animals were anesthetized, theirtracheas cannulated and BALF extracted by infusing and then withdrawingfrom their lungs 1.0 mL of PBS via the tracheal catheter. Total anddifferential white cell counts in the BALF samples were measured using aNeubaur haemocytometer. Cytospin smears of the BALF samples wereprepared by centrifugation at 200 rpm for 5 min at RT and stained usinga DiffQuik stain system (Dade Behring). Cells were counted using oilimmersion microscopy. Data for neutrophil numbers in BAL are shown asmean±S.E.M. (standard error of the mean). The percentage inhibition ofneutrophil accumulation was calculated for each treatment relative tovehicle treatment.

Cigarette Smoke Model

A/J mice (males, 5 weeks old) were exposed to cigarette smoke (4%cigarette smoke, diluted with air) for 30 min/day for 11 days using aTobacco Smoke Inhalation Experiment System for small animals (ModelSIS-CS; Sibata Scientific Technology, Tokyo, Japan). Test substanceswere administered intra-nasally (35 μL of solution in 10% DMSO/PBS) oncedaily for 3 days after the final cigarette smoke exposure. At 12 h afterthe last dosing, each of the animals was anesthetized, the tracheacannulated and bronchoalveolar lavage fluid (BALF) was collected. Thenumbers of alveolar macrophages and neutrophils were determined by FACSanalysis (EPICS® ALTRA II, Beckman Coulter, Inc., Fullerton, Calif.,USA) using anti-mouse MOMA2 antibody (macrophage) or anti-mouse 7/4antibody (neutrophil). BALF was centrifuged and the supernatant wascollected. The level of keratinocyte chemoattractant (KC; CXCL1) in BALFwas quantitated using a Quantikine® mouse KC ELISA kit (R&D systems,Inc., Minneapolis, Minn., USA).

In Vivo Screening: Pharmacodynamics and Anti-Inflammatory Activity (notEmployed in the Examples)

The following in vivo screens could be employed to assess the compoundof the present invention:

DSS-Induced Colitis in Mice

Non-fasted, 10-12 week old, male BDF1 mice are dosed by oral gavagetwice daily with either vehicle, reference item (5-ASA) or test compoundone day before (Day −1) stimulation of the inflammatory response bytreatment with DSS. On Day 0 of the study DSS (5% w/v) is administeredin the drinking water followed by BID dosing of the vehicle (5 mL/kg),reference (100 mg/kg) or test compound (5 mg/kg) for 7 days. Thedrinking water with DSS is replenished every 3 days. During the studyanimals are weighed every day and stool observations are made andrecorded as a score, based on stool consistency. At the time ofsacrifice on Day +6 the large intestine is removed and the length andweight are recorded. Sections of the colon are taken for either MPOanalysis to determine neutrophil infiltration or for histopathologyscoring to determine disease severity.

TNBS-Induced Colitis in Mice

Non-fasted, 10-12 week old, male BDF1 mice are dosed by oral gavagetwice daily with either vehicle (5 mL/kg), reference item (Budesonide2.5 mg/kg) or test compound (1, 5 or 50 mg/kg) one day before (Day −1)stimulation of the inflammatory response by treatment with2,4,6-trinitrobenzenesulphonic acid (TNBS) (15 mg/mL in 50% ethanol/50%saline). On Day 0 of the study TNBS (200 μL) is administeredintra-colonically via a plastic catheter followed by BID dosing of thevehicle, reference or test compound for 2 or 4 days. During the studyanimals are weighed every day and stool observations are made andrecorded as a score, based on stool consistency. At the time ofsacrifice on Day 2 (or Day 4) the large intestine is removed and thelength and weight recorded. Sections of the colon are taken for eitherMPO analysis to determine neutrophil infiltration or for histopathologyinvolving scoring to determine disease severity.

Adoptive Transfer in Mice

On study day 0, female Balb/C mice are terminated and spleens obtainedfor CD45RB^(high) cell isolation (Using SCID IBD cell Separationprotocol). Approximately 4×10⁵ cells/mL CD45RB^(high) cells are theninjected IP (100 μL/mouse) into female SCID animals. On study day 14,mice are weighed and randomized into treatment groups based on bodyweight. On day 21, compounds are administered BID, via oral gavage, in apeanut oil vehicle at the dose levels outlined below and a dose volumeof 5 mL/kg. Treatment continues until study day 42, at which point theanimals are necropsied 4 h after a.m. administration. The colon lengthand weight is recorded and used as a secondary endpoint in the study asa measurement of colon oedema. The colon is then divided into sixcross-sections, four of which are used for histopathology scoring(primary endpoint) and two are homogenised for cytokine analysis. Datashown is the % inhibition of the induction window between naïve animalsand vehicle animals, where higher inhibition implies closer to thenon-diseased, naïve, phenotype.

In Vitro and In Vivo Screening Results

In vitro screening results for the compound of the invention (free baseform) are set out in Table 2, Table 3, Table 4 and Table 5 below andFIG. 9. Comparison is made with a structurally related ReferenceCompoundN-(4-(4-(3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)-2-methoxyacetamide(Example 1 of WO2010/112936), which has been previously described as apotent anti-inflammatory agent with anti-viral effects, as well as withfluticasone propionate which is a well known anti-inflammatory agent.

TABLE 2 p38 MAPKα and γ, HCK, c-Src, Syk and GSK3α Enzyme Profile ofTest Compounds IC₅₀ Values for Enzyme Inhibition (nM) Test p38 p38Compound MAPKα MAPKγ HCK c-Src Syk GSK3α Reference 10 87 7 11 42 18Compound Compound 26 152 55 199 >15955 >15105 of the invention

TABLE 3 Inhibition of LPS Induced TNFα and IL-8 Release and PolyICInduced ICAM-Expression for Test Compounds LPS Induced Release (nM)PolyIC/ IL-8 TNFα ICAM1 (nM) Test IC₅₀ (dU937) REC₅₀ IC₅₀ (BEAS2B)Compound (dU937) Reference 1.2 0.7 3.8 Compound Compound of 11.4 5.561.1 the invention

TABLE 4 Effect of Test Compounds on Cell Viability Mitosis Assay² MTTAssay¹ Inhibition Cell viability at time point (%) of indicated ind-U937 Cells mitosis Test 4h 24h At 5 ug/mL Compound Reference − + 93 ±5 Compound Compound of − − 18 ± 7 the invention 1. Cell viabilityscreen: − ve and + ve indicate the value is below and above,respectively, the no significant effect threshold defined as 30%inhibition at 10 μg/mL at the time point indicated. 2. Mean ± SEM

TABLE 5 Effect of Test Compounds on cytokine production in LPS-treatedsputum macrophages from COPD patients Percent Inhibition at 0.1 μg/mLTest IL-6 Compound Fluticasone 29 ± 21 propionate Compound of 48 ± 9 the invention

Summary of In Vitro and In Vivo Screening Results

The compound of the invention demonstrates a profile in in vitro and invivo assays consistent with good anti-inflammatory activity. It has veryweak activity at Syk and GSK3α kinases (Tables 2 and 3).

The compound of the invention shows markedly less activity in assaysystems that measure its impact on cell viability indicating that it islikely to possess a superior therapeutic index over the ReferenceCompound (Table 4).

The compound of the invention showed superior anti-inflammatory activitycompared to fluticasone propionate in the assay system used (Table 5).

The compound of the invention shows dose-dependent inhibition ofHRV-induced IL-8 (FIG. 9).

In summary, these results suggest that the compound of the invention hassimilar anti-inflammatory properties to the Reference Compound disclosedabove and, advantageously, is associated with a superior therapeuticindex.

What is claimed is:
 1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof.
 2. A compound accordingto claim 1 in the form of its maleate salt.
 3. A compound according toclaim 2 in the form of its Form 2 crystalline polymorph.
 4. Apharmaceutical composition comprising a compound of formula (I)according to claim 1 in combination with one or more pharmaceuticallyacceptable diluents or carriers.
 5. A pharmaceutical compositioncomprising a compound of formula (I) according to claim 1 in particulateform in combination with particulate lactose.
 6. A pharmaceuticalcomposition according to claim 5 further comprising particulatemagnesium stearate.
 7. A combination product comprising: (A) a compoundaccording to claim 1; and (B) one or more other therapeutic agents,wherein each of components (A) and (B) is formulated in admixture with apharmaceutically-acceptable adjuvant, diluent or carrier.
 8. A method oftreatment of a condition selected from the group consisting of COPD,asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathicpulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergicconjunctivitis, conjunctivitis, keratoconjunctivitis sicca, glaucoma,diabetic retinopathy, macular oedema, central retinal vein occlusion,dry and/or wet age related macular degeneration, post-operative cataractinflammation, uveitis, corneal graft and limbal cell transplantrejection, gluten sensitive enteropathy, eosinophilic esophagitis,intestinal graft versus host disease, Crohn's disease, ulcerativecolitis, IBD, rheumatoid arthritis and osteoarthritis which comprisesadministering to a subject an effective amount of a compound ofaccording to claims claim
 1. 9. A method according to claim 8 whereinthe condition is COPD or asthma.
 10. A pharmaceutical compositionaccording to claim 4 wherein the compound of formula (I) is in the formof its maleate salt.
 11. A pharmaceutical composition according to claim5 wherein the compound of formula (I) is in the form of its maleatesalt.
 12. A pharmaceutical composition according to claim 6 wherein thecompound of formula (I) is in the form of its maleate salt.
 13. Acombination product according to claim 7 wherein the compound of formula(I) is in the form of its maleate salt.
 14. A method according to claim8 wherein the compound of formula (I) is in the form of its maleatesalt.
 15. A pharmaceutical composition according to claim 10 wherein thecompound of formula (I) maleate salt is in the form of its Form 2crystalline polymorph.
 16. A pharmaceutical composition according toclaim 11 wherein the compound of formula (I) maleate salt is in the formof its Form 2 crystalline polymorph.
 17. A pharmaceutical compositionaccording to claim 12 wherein the compound of formula (I) maleate saltis in the form of its Form 2 crystalline polymorph.
 18. A combinationproduct according to claim 13 wherein the compound of formula (I)maleate salt is in the form of its Form 2 crystalline polymorph.
 19. Amethod according to claim 14 wherein the compound of formula (I) maleatesalt is in the form of its Form 2 crystalline polymorph.